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ABSTRACT 
In the past 30 years developed and developing countries faced significant lifestyle 
changes that made the incidence of diabetes mellitus to reach pandemic proportion 
worldwide. This increase, seen in both types of the disease, made diabetes mellitus one of the 
leading causes of morbidity and mortality of our times. Bone is one t of several organs that 
are affected by diabetes mellitus, being morbidity caused by bone fractures highly correlated 
to diabetic bone. Alterations in the constituents of bone, microarchitecture changes and bone 
loss have been pointed as the main reasons for its fragility. This work aimed to contribute to 
identify the molecular players or the functional changes affecting bone and caused by diabetes 
mellitus. In chapter 2, using as animal model of type 1 diabetes mellitus the Ins2+/akita mouse, 
we identified bone growth retardation related to growth plate impairment. These changes were 
associated to reduced expression of Igf1 and increased expression of cartilage degradation 
enzymes like Adams-5. We also identified severe microarchitecture changes caused by 
reduced bone formation and resorption that could be explained by leptin deficiency and/or 
decreased insulin signaling. In chapter 3, we concluded that paricalcitol (vitamin D analog) 
and cinacalcet (calcimimetic), two drugs used for the treatment of secondary hyperthyroidism, 
have beneficial effects in fin regeneration and mineralization in a zebrafish model of diabetes. 
These results could be explained by the downregulation of pthr suggesting reduced signaling 
of parathyroid hormone, that is a potent activator of bone remodeling, and increased 
expression of runx2, indicating increased osteoblast differentiation. Increased expression of 
the two zebrafish insulin genes, insa and insb, could be observed, suggesting that both drugs 
promote an increase in insulin signaling. In chapter 4, we suggest that in humans, the insulin 
paralog gene, INS-IGF2, does not have a redundant function with the insulin gene, in contrast 
with what is seen in mice and probably in zebrafish. We could also conclude that 
extrapancreatic expression of insulin is present in human, mouse and zebrafish. In humans 
 xii 
this expression results mainly from expression of the ancestral gene while  in mice and 
zebrafish it is due to expression of the insulin paralogues. 
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RESUMO 
Alterações significativas no estilo de vida nos países desenvolvidos e em 
desenvolvimento, durante as ultimas décadas, fizeram com que a incidência da diabetes 
mellitus tenha tomado proporções semelhantes às de uma pandemia. Este aumento, observado 
em ambos os tipos da doença, fez com que diabetes mellitus se tenha tornado uma das 
principais causas de morbidade e mortalidade dos nossos tempos. O osso está entre os vários 
órgãos que são afetados pela diabetes mellitus, estando a morbidade causada por fraturas 
ósseas, altamente correlacionada com esta doença. Perda óssea, alterações nos constituintes e 
na microarquitetura do osso, têm sido apontadas como os principais causas para a fragilidade 
óssea destes pacientes. Neste trabalho propusemo-nos identificar intervenientes moleculares 
que estão envolvidos nas alterações ósseas despoletadas pela diabetes mellitus. No capítulo 2, 
usando como modelo animal de diabetes mellitus tipo 1 o ratinho Ins2+ /akita, procurámos 
identificar alterações histomorfométricas na estrutura do osso e cartilagem e identificar genes 
com a expressão alterada através de PCR em tempo real quantitativo. Pudemos observar 
diminuição no crescimento ósseo causado por uma redução no número de condrócitos 
proliferativos e aumento no número de condrócitos hipertróficos na placa de crescimento. 
Estas alterações foram acompanhadas por uma redução na expressão de fatores de 
crescimento como a Igf1 e aumento da expressão de enzimas responsáveis pela degradação da 
cartilagem como Adams-5. Igualmente, pudemos observar alterações profundas na 
microarquitetura do osso do ratinho Ins2 +/akita, que sugerem reduzida formação e reabsorção 
óssea. O facto de a diabetes mellitus tipo 1 estar associada a um estado de hipoleptinémia e 
hipoinsulinémia faz com que ambas as hormonas, leptina e insulina, sejam as principais 
candidatas a explicar as alterações observadas, visto que ambas desempenham um papel 
ativador da função dos osteoblastos e osteoclastos. No capítulo 3, tentamos perceber se a 
vitamina D, análogos da vitamina D e calcimiméticos, podem ter um papel benéfico na 
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regeneração e mineralização óssea na diabetes mellitus tipo 1. Foi possível concluir que os 
medicamentos paricalcitol (análogo da vitamina D) e cinacalcet (calcimimético), usados para 
o tratamento do hipertiroidismo secundário, têm efeitos benéficos na regeneração e 
mineralização da barbatana caudal num modelo de diabetes mellitus tipo 1 de peixe-zebra. 
Estes resultados poderão ser explicados pela diminuição da expressão da pthr, que sugere uma 
redução da hormona paratiróide circulante, que é um activador da remodelação óssea, e um 
aumento da expressão de runx2, que sugere maior diferenciação dos osteoblastos, assim como 
um aumento da expressão de ambos os genes insa e insb da insulina no osso, sugerindo que 
estes medicamentos poderão por um lado aumentar a expressão extrapancreática no osso e por 
outro a expressão pancreática, aumentando assim a sua sinalização nas células alvo. No 
capítulo 4 concluímos que nos humanos, o gene parálogo da insulina, o INS-IGF2, não tem 
uma função redundante em contaste com o que foi observado nos ratinhos e, provavelmente, 
no peixe-zebra. Foi também possível concluir que a expressão extrapancreática da insulina 
ocorre em humanos, ratinho e peixe-zebra e que nos humanos este fenómeno é devido 
principalmente à expressão do  gene ancestral, enquanto no ratinho e no peixe-zebra parece 
ser devido à expressão dos parálogos respectivos. 
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CHAPTER 1. GENERAL INTRODUCTION 
1.1. Type 1 Diabetes Mellitus  
1.1.1. Prevalence  
Diabetes mellitus (DM) is the most rapidly growing chronic disease of our time. 
In developed and developing countries is predicted to occur a decrease in life 
expectancy for the first time in 200 years because of DM [1]. In 2011 there were 366 
million people with DM and expected to rise to 552 million by 2030 [2] with a 
estimation of being the 7th leading cause of death in 2030 [3]. Population growth, 
aging, urbanization, and growing prevalence of obesity and physical inactivity are 
between the principal causes. Originally expected to occur in type 2 diabetes mellitus 
(T2DM), the increase in childhood diabetes has been of both type 1 and 2 DM [4] 
 
 
 
Figure 1. .Estimates and projections of global diabetes prevalence. All projections from different studies 
suggest growing prevalence of diabetes over the next decades. GBD, Global Burden Diabetes, IDF, 
International Diabetes Federation, WHO, World Health Organization. Adapted from Whiting et al., 2011. 
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Type 1 diabetes mellitus (T1DM) accounts for 10% of all DM cases [2] with an 
increasing incidence of 2-5% a year [5]. Although the reasons for this increase are still 
unknown, genetic susceptibility together with environmental factors suggest that a 
multifactorial process might be involved [6]. Children with T1DM have in 90–95% of 
incidences a susceptibility in the human leukocyte antigen complex in chromosome 6 
[7], but only 5% of the individuals that carry this susceptibility actually develop the 
disease [8] supporting the idea that other factors are needed to trigger T1DM.  
1.1.2. Causes  
T1DM is divided in two sub-groups, the most common is type 1a that is linked 
to an autoimmune-mediated destruction of beta cells, while in type 1b are included rare 
forms of the disease associated to genetic defects in beta-cell function, with a sub-
classification according to the gene involved.  
Type 1a of DM is characterized by a disorder of glucose homeostasis by 
susceptibility to ketoacidosis. Besides the genetically heterogeneous autoimmune 
predispositions, environmental triggering hypothesis have been made like hygiene, viral 
infections, vitamin D deficiency, breast milk and cow's milk [6]. At the present time, the 
hygiene hypothesis seems to be the best candidate to explain onset of the disease. 
Strachan [9] proposed that exposure to a variety of infectious agents during early 
childhood might be protective. Beside this, authors suggest that the reason for the 
increase in the incidence of the disease probably is multifactorial [6].   
Type 1a DM results in a dysregulation to self-tolerance proteins. During thymus 
development, T-cells that do not express highly self-reactive T cell receptors mature and 
leave the thymus while highly autoreactive T cells are deleted in healthy individuals. 
But in T1DM these highly autoreactive T cells are not eliminated and escape to the 
periphery participating in the pathological immune response to self-antigens.     
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Type 1b DM, also called monogenic diabetes of infancy, is a broad definition 
of diabetes, permanent or transient, during the first years of life with onset caused by a 
single gene defect [10]. Candidate gene defects are homozygous or heterozygous 
mutations in potassium inwardly-rectifying channel, subfamily J, member 11 
(KCNJ11), Glucokinase (GCK), ATP-binding cassette transporter sub-family C 
member 8 (ABCC8) and insulin genes [11]. It is characterized by patients without 
pancreatic autoantibodies, implying that these β-cells malfunction is caused by a 
mutation and not from autoimmune response.  
1.1.3. Pathophysiology  
Abnormalities in β-cell functions leads to reduced insulin secretion that starts 
before the onset of symptoms.  Low insulin activity results in increased glucose 
production by the liver and reduced glucose uptake by insulin sensitive tissues. As 
glucose accumulates in plasma, renal tubules are incapable of reabsorbing all the 
glucose, producing an osmotic diuresis. As insulin sensitive cells are deprived from 
glucose, fat and muscle breakdown is initiated to use free fatty acids and amino acids as 
fuels for glucose production by the liver, leading to weight loss. Accelerated fatty acids 
breakdown leads to overproduction of ketone bodies, leading to ketoacidosis and 
together with hyperglycemia and acidosis creates a fatal condition, if insulin therapy is 
not initiated [12]. 
Hypoinsulinemia has been associated to the dysregulation of several other 
hormones that also mediate the onset of T1DM. Lack of insulin signaling in adipocytes 
leads to low secretion of leptin, leading to increased hypothalamic pituitary adrenal 
(HPA) axis activity that centrally will increase glucagon, adrenocorticotropic hormone 
(ACTH) and corticosterone plasma concentration [13,14].  
 8 
 
Figure 2. T1DM leads to hyperglycemia and ketoacidosis. Hypoinsulinemia decreases plasma leptin 
concentration by decreasing its secretion from adipose tissue. Low insulin and leptin secretion increase 
glucagon production by α-cells, signaling glucose release by the liver. Low leptin increases 
hypothalamus-pituitary-adrenal (HPA) axis activity and Adrenocorticotropic hormone (ACTH) release 
from the pituitary, increasing cortisol secretion from the adrenal glands and induce lipolysis of adipose 
tissue triglycerides. The increased release of free fatty acids (FFAs) and glycerol from adipose tissue into 
the bloodstream increases the delivery of glycerol and fatty acids substrates to the liver. Incomplete 
oxidation of fatty acids in the liver produces ketone bodies and increases hepatic acetyl-CoA, contributing 
to hyperglycemia by increasing the conversion of pyruvate to glucose. Adapted from Mittendorfer & 
Klein., 2014. 
 
In is work , Perry et al. [15] could see that leptin treatment reduced glucagon 
production, and that gluconeogenesis and fat breakdown in poorly controlled T1DM 
rats was caused by hypoleptinemia induced activity of the HPA and more importantly, 
that changes could be dissociated from insulin concentrations.    
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1.2. Bone  
1.2.1. Formation 
Bone homeostasis is achieved by balanced activity of bone forming cells, the 
osteoblasts, and bone resorption cells, the osteoclasts. Osteoblasts are responsible for 
the secretion of a group of extracellular proteins that will give rise to the extracellular 
bone matrix. This includes osteocalcin, alkaline phosphatase and a large amount of type 
I collagen. First a non-mineralized matrix is formed, constituted by type 1 collagen, 
named osteoid and later mineralized through the accumulation of calcium phosphate in 
the form of hydroxyapatite, leading to the formation of  the major mineral constituent of 
bone [16].  
 
Figure 3. Bone homeostasis is accomplished by osteoclasts and osteoblasts. A) Osteoblasts arise from 
mesenchymal progenitors (MP) through preosteoblasts and then becomes another type of osteoblast 
lineage cell, the osteocytes, after being trapped in the bone matrix. Osteoclasts are multinucleated 
resorptive cells derived macrophages, which are in turn progenies of hematopoietic stem cells (HSCs). B) 
Osteoblasts differentiate from MP through intramembranous or endochondral ossification. In 
intramembranous ossification, MP condenses and differentiates into osteoblasts. In endochondral 
ossification, they condense and differentiate into perichondrial cells and chondrocytes, the latter undergo 
hypertrophy, which triggers the differentiation of perichondrial cells to osteoblasts. Adapted from Long, 
2014.  
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Osteoblasts are generated from mesenchymal cells through two distinct 
processes: intramembranous or endochondral ossification. During intramembranous 
ossification, mesenchymal progenitors condense and directly differentiate into 
osteoblasts. But in endochondral ossification, mesenchymal progenitors condense to 
form chondrocytes and perichondrial cells. Chondrocytes proliferate and undergo 
hypertrophy, and only then do osteoblasts differentiate from the perichondrial cells [17]. 
1.2.2. Transcription factors involved in osteoblast differentiation  
Osteoblasts differentiation from mesenchymal stem cells initiates by the action 
of SRY (Sex Determining Region Y)-Box 9 (SOX9) and although SOX9 is 
indispensable for chondrogenesis, it also marks the mesenchymal progenitors that give 
rise to all osteoblasts. However, SOX9 is not expressed by mature osteoblasts.  
 
Figure 4. The different stages of osteoblast lineage cell differentiation. Mesenchymal progenitors that 
give rise to osteoblasts and chondrocytes are initially marked by the transcription factor SOX9. This is 
followed by the expression of RUNX2 and then OSX, leading to the development of osteoblasts. Some 
osteoblasts become osteocytes by being entombed in the bone matrix. SOX9 cells are bipotential and can 
also differentiate into chondrocytes. Dashed arrows represent that during development osteoblasts can 
switch fates under these conditions. . Adapted from Long, 2014.  
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During the process of differentiation, preosteoblasts are characterized by the expression 
of runt-related transcription factor 2 (RUNX2) and, in a more advanced stage of 
differentiation, both RUNX2 and osterix (OSX), while mature osteoblasts are 
characterized by the expression of osteocalcin [16]. Then a part of osteoblasts become 
osteocytes being trapped within the bone matrix and the rest either go into apoptosis or 
become inactive bone lining cells [18]. 
1.2.3. Remodeling 
Once formed, bone undergoes remodeling that involves resorption and the 
formation of new bone; this occurs in micro scale throughout the skeleton. Bone 
remodeling is the predominant metabolic process regulating bone structure and function 
during adult life [19]. The cell type responsible for this process is the osteoclast, a 
tissue-specific macrophage polykaryon created by the differentiation of haematopoietic 
stem cells (HSCs) lineage at or near the bone surface. Mature osteoclasts activity is 
triggered by activation of receptor activator of nuclear factor (NF)-kB (RANK) by 
RANK ligand (RANKL) expressed by osteoblasts [20]. After its activation, osteoclasts 
undergo internal structural changes that prepare it to resorb bone, such as the 
rearrangements of the actin cytoskeleton and formation of a tight junction between the 
bone surface and basal membrane to form a sealed compartment. This external vacuole 
is then acidified by the export of hydrogen. Secretion continues with the export of the 
lytic enzymes TRAP and pro-CATK into a resorption pit. Through this process the 
osteoclast erodes the underlying bone. Degradation products, collagen fragments and 
solubilized calcium, phosphate and undercarboxylated osteocalcin are processed within 
the osteoclast and released into the circulation [16]. 
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1.3. Bone Health in Type 1 Diabetes Mellitus  
1.3.1. T1DM and bone loss 
It is well established that T1DM is linked to a decrease of bone mineral density 
(BMD) and bone loss in humans [21–26], mice [27–32] and also in fin regeneration in 
zebrafish [33]. Different factors have been identified as responsible for this outcome. 
T1DM reduces osteoblast activity, as determined by serum osteocalcin levels which 
were found to be decreased in DMT1 mice models [31,34,35]. mRNA levels were also 
found to be reduced and associated with a reduced rate of mineral apposition [31,36–
38]. In addition, several studies have demonstrated an increase in terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive dying 
osteoblasts in diabetic compared to control [39,40]. So, enhanced osteoblast death 
caused by T1DM contributes to a reduction in osteoblast number and activity. In DMT1 
mice models, osteoclast activity does not appear to be altered or decreased [36,41] in the 
majority of DMT1 studies, with only a few studies showing increased osteoclast 
markers [42], but this was proposed to be linked to the dose of streptozotocin used to 
induce diabetes in this model. 
1.3.2. Insulin signaling and IGF1 
Insulin plays an important role in bone growth due to its anabolic properties. 
Mice with 3–6 weeks, with insulin receptor (IR) deletion in osteoblasts revealed 
reduced bone volume and osteoblast number [43]. Also it has been proposed that insulin 
signaling in osteoblasts is necessary for whole-body glucose homeostasis, because 
insulin signaling in osteoblasts increase bone resorption by osteoclasts.  With the 
increase in bone resorption, osteocalcin in its  undercarboxylated form is released into 
the blood stream and acts as a hormone, signaling insulin expression in β-cells and other 
sensitive tissues [44,45]. Furthermore, animal models and cell studies showed that 
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osteocalcin can increase cell proliferation, stimulate insulin expression and secretion by 
pancreatic cells and enhance energy expenditure [43,46,47].  
 
Figure 5. Model of action of insulin in bone resorption and osteocalcin regulation of insulin expression. 
Insulin signaling in osteoblasts decreases osteoprotegerin (Opg) expression. The decrease in the 
OPG/RANKL ratio results in an increased expression of Tcirg1 in osteoclasts. Tcirg1 encodes for a 
proton (H+) pump subunit and contributes to acidification of the resorption lacunae. The acidic pH of 
approximately 4,5 generated during bone resorption is a sufficient mean to decarboxylate and activate the 
osteocalcin molecules (Gla-OCN) stored in the bone extracellular matrix. The undercarboxylated active 
osteocalcin (Glu-OCN) promotes insulin sensitivity in peripheral organs and stimulates insulin secretion 
by the β-cells of the pancreas. Adapted from Clemens and Karsenty, 2011. 
 
Insulin growth factor 1 (GF1) is crucial for postnatal skeletal growth. Although 
it is mostly known for its effect on growth plate cartilage, it also regulates various 
aspects of osteoblast lineage cells metabolism [48]. IGF1 is regulated centrally by 
growth hormone (GH) and mainly produced by the liver. The direct effects of IGF1 on 
bone could be seen when IGF1 receptor (IGF1R) knockout (KO) mice specifically in 
osteoblasts treated with GH failed to increase osteoblast number and osteoblast-specific 
deletion or overexpression of IGF1R reduced or increased bone formation [49,50]. 
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1.3.3. Advanced glycation end products (AGEs)  
Hyperglycemia increases nonenzymatic protein glycation, leading to the 
formation of a variety of chemically modified proteins known as advanced glycation 
end products (AGEs). Type 1 collagen is a target for AGEs leading to an increase in 
non-enzymatic collagen glycation [34], by forming covalent cross-links with collagen 
molecules through enzymatic reactions. AGEs are associated with reduced osteocalcin 
levels, inhibiting osteoblastic cells function [51], increasing cell clumping and 
decreasing cellular spreading [52]. AGEs increase with age and are accumulative and 
irreversible. Diabetic bone also exhibit increase in AGEs receptor (RAGE) causing 
AGEs increase [53]. In turn RAGE activation initiates inflammatory signals that 
stimulate a generation of reactive oxygen species and inflammation mechanisms which 
enhance AGE formation [54].    
 
Figure 6. Principal causes for accumulation of AGEs in bone. Oxidative stress, high glucose, aging 
processes, and low bone turnover contribute to an increased formation and accumulation of AGEs in 
bone. Together with an increase of certain pro-inflammatory cytokines, AGEs induce both the activation 
of osteoclastogenesis and osteoblast dysfunction; leading to an accelerated development of osteoporosis. 
Adapted from Sanguineti et al. 2014.  
 
1.3.3.1. Inflammation  
 Bone inflammation has been linked to T1DM, principally because of AGEs or 
by autoimmunity reaction in T1DM.  
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It is currently assumed that both types 1 and 2 diabetes are associated with 
inflammation [37,40,55]. RAGE cell expression leads to activation of inflammation and 
tissue damage, upregulating inflammatory mediators like tumor necrosis factor-alpha 
(TNF-α), interleukin-1 (IL-1), IL-6, and C-reactive protein (CRP) [54]. These suggest 
that RAGE activation contributes to perpetuation of AGEs and pro-inflammatory 
ligands synthesis, generating a microenvironment favorable for ligands production and 
suppressing protective mechanisms [56]. Diabetic mice models have demonstrated 
elevated TNF-α mRNA expression in bone marrow and is linked to early osteoblast 
death [37,57]. Treatment with TNF-α inhibitors reduced diabetes-induced increase in 
osteoblast apoptosis [58,59], suggesting a role for inflammation within the bone marrow 
in inducing osteoblast death. 
1.3.4. Bone marrow adiposity  
Both osteoblasts and adipocytes derive from MSC, this evidence has led to the 
assumption that lineage selection, adipocyte over osteoblast, could be involved in the 
diminishing of BMD due to an increase in bone marrow adiposity . Although an 
increase in marrow adiposity has been observed in some T1DM mice models [31,37], 
this relation is not seen in the vertebrae where there is a loss of bone but no increase in 
bone marrow adipocytes [60]. Supporting this idea are the results obtained from treating 
bone marrow adipocytes, either with PPARƴ antagonist [61] or with leptin [60], where, 
in both cases, it was possible to prevent marrow adiposity but in neither of the 
treatments bone loss was prevented. This finding suggests that T1DM bone marrow 
adiposity increase in some T1DM mice models alone couldn´t be the cause for a 
decrease in bone volume [27]. 
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1.3.5 Leptin and T1DM 
The regulation of bone by leptin has been one of the major findings in the field 
of bone metabolism in the last fifteen years. Leptin is an adipocyte-derived hormone 
that is traditionally associated with controlling appetite and reproduction. But it was 
proposed that leptin signaling, through its receptors in the hypothalamus, stimulates 
noradrenaline secretion, that binds to β2-adrenergic receptors (Adrb2) on osteoblasts, 
inhibiting bone formation and increasing RANKL secretion, thus leading to increase 
bone resorption by osteoblasts [62]. After this findings several works have focused in 
understanding how leptin regulates bone and to explain the phenotype of the leptin KO 
ob/ob mice that have increased trabecular bone volume, but decreased cortical bone 
mass [63–65]. The most important matter of debate at the present moment, is if leptin 
regulates bone centrally or peripherally or by both ways. After the work of Ducy et al. 
[66], Steppan et al. [67] could see increase in bone mineral density after peripheral 
administration of leptin in ob/ob mice (although leptin can cross the blood-brain barrier 
and could have acted centrally) and similar results could be seen by Burguera et al. [68].   
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Figure 7. Models proposed for action of leptin on bone. A) Ducy’s model, leptin indirectly inhibits bone 
formation through an hypothalamic relay. B) Burguera/Hamrick model, skeletal effects of leptin result 
from anabolic actions of peripheral leptin and antiosteogenic actions of hypothalamic leptin. C) Turner 
model, leptin directly increases bone growth, osteoblast number and function, as well as osteoclast 
function. These physiological actions of the hormone are largely mediated through peripheral leptin 
signaling. Solid arrows represent the major route of action of action. The question mark indicates that 
mediation of the leptin-dependent increase in osteoclast activity by the osteoblast is speculative. Adapted 
from Turner et al., 2013. 
 
Later, Hamrick et al. [63] reported that, consistent with observations from the 
Karsenty group, ob/ob mice exhibit a high bone mass in the lumbar vertebrae, but a 
contrastingly low trabecular and cortical bone mass in the femur, proposing a 
concurrence of both axial catabolic and appendicular anabolic effects of leptin on the 
skeleton. Finally, Turner et al. [65] was extremely polemic about the work of Ducy et 
al. [66] saying that the central regulation of leptin is not the principal pathway for the 
regulation of bone and the direct signaling of leptin through the leptin receptors  in both 
osteoblasts and osteoclasts enhance bone formation and bone resorption respectively.  
Independently from how leptin acts in bone, it is widely assumed that low levels 
of leptin secretion induce changes in bone homeostasis. Low controlled T1DM patients 
also develop hypoleptinemia, another important factor in the diabetic bone phenotype.     
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1.4. T1DM animal models used in our study 
1.4.1. Ins2+/akita mouse 
Mice have two different genes for insulin, Ins1 and Ins2, the latter being the 
ortholog for human INS gene. Ins2+/akita mouse, first generated in 1997 by Yoshioka and 
colleagues [69], have only one allele (Ins2) mutated. The mutant allele is characterized 
by a transition from G to A at nucleotide 1907 disrupting an Fnu4HI site in exon 3. This 
mutation changes the seventh amino acid in the A chain of mature insulin, from Cys96 
(TGC), to Tyr (TAC).  
 
Figure 8. Diabetes of the Ins2+/akita mouse is caused by a single locus mutation, and is inherited in an 
autosomal dominant manner. A GA mutation changed amino acid Cys96 (TGC) to Tyr (TAC). Cys96 
corresponds to the seventh amino acid in the A chain (A7) of mature insulin and forms one of the three 
intramolecular disulfide bonds with Cys31 located at B7 [70]. Adapted from Støy J et al. 
 
This cysteine residue normally forms an intramolecular disulfide bond with 
cysteine at B7. Disruption of the disulfide bonds is expected to induce a drastic 
conformational change of the molecule. Normal and mutant Ins2 alleles are transcribed 
similarly in pancreatic islets of heterozygous mice, although immunofluorescence and 
immunoblot analyses detected reduced levels of insulin and proinsulin [69], rendering β 
cells incapable of insulin secretion in a dominant negative way [71].  
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Two of the proteins playing a major role in regulation of Ins2, protein disulfide 
isomerase (PDI) and binding immunoglobulin protein (BiP), are overexpressed in the 
islets of Ins2+/akita mice. Both proteins reside in the ER, where disulfide formation and 
folding of secreted protein occur. Disulfide formation can be formed in the wrong 
temporal order and even randomly in some proteins. In this case, lack of cysteine at A7 
in the mutant proinsulin will leave cysteine at B7 free and thereby increase the 
possibility that later, cysteine forms incorrect disulfide bonds with other molecules. This 
would affect the disulfide bond formation of coexisting wild-type proinsulin and result 
in an aggregation in Ins2+/akita mice .  
 
Figure 9. Pathway of preproinsulin to insulin in WT and Ins2+/akita mice. In Ins2+/akita mouse, mutant 
proinsulin will acquire a deficient structure, becoming unable to exit the ER. The seventh amino acid of 
the B chain will create a disulfide bond, with the seventh amino acid of the A chain of proinsulin non 
mutated allele, forming an aberrant structure. This protein will not be expressed and it will be eliminated. 
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 This form of T1DM, modeled by Ins2+/akita mouse [69,71,72], is also seen in 
humans [7-9] and is part of the sub-group Type 1b DM or permanent neonatal diabetes 
mellitus (PNDM). 
Symptoms in heterozygous Ins2+/akita mutant mice include hyperglycemia, 
hypoinsulinemia, hypoleptinemia, polydipsia, and polyuria, beginning around 3-4 
weeks of age but no obesity, infertility, or immunological alterations have been 
described to date in these mice. Histological signs of glomerulosclerosis have also been 
described in 20-wk-old Ins2+/akita mice and renal function impairment after age 30 
weeks [73]. But although this model develops bone loss, with a clear decrease in bone 
mineral density, no histological characterization of its bone structure/morphology or any 
in vitro work using Ins2+/akita at adult and aging time points is available. 
1.4.2. Transgenic zebrafish Tg(ins:Eco.NfsB-mCherry) 
With the objective of generating a zebrafish model of β-cell regeneration, Pisharath and 
colleagues [74] inserted an Escherichia coli gene downstream from the promoter region 
of insa gene called nfsB. This bacterial gene encodes a nitroreductase (NTR) enzyme, 
which can convert prodrugs such as metronidazole (Met) to cytotoxins. By fusing nfsB 
to a mCherry florescent protein, it is possible to visualize insa expressing cells and 
ablation of β-cells 3 days after an intraperitoneal (IP) injection with Met.  
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After this period, increased blood glucose can be detected and progressive 
regeneration of β-cells leads to normalization of glycaemia after two weeks of Met 
exposure [75]. Also it was observed that after 3 day exposure to Met, blood glucose 
readings were higher than in the streptozotocin (STZ) induced diabetic WT zebrafish, 
suggesting that β-cell ablation may be more complete in the Tg(ins:Eco.NfsB-
mCherry), making this model more suitable for the study of diabetes [76]. 
Also it was observed that β-cell ablation was achieved without affecting the 
neighboring α and δ cells [74]. During the window period of induced hypoinsulinemia, 
different protocols can be applied to study the effects of DM, also the hyperglycemic 
state can be prolonged if continuous exposure to Met is applied.    
 
 
 
 
 
Nitroreductase 
Prodrug 
Metronizadol cytotoxic 
C 
nfsB 
transcript 
product
A 
Figure 10. Transgenic zebrafish Tg(ins:Eco.NfsB-mCherry) is a suitable model to study DM; A This model as 
a e.coli gene nfsB and a mCherry florescent protein downstream of the promoter region of the insa gene; B
Transgenic larvae with florescent insa expressing cells, mainly the pancreas; C nitroreductase enzyme from 
nfsB  gene  catalysis Met generating a cytotoxic compound induced ablation in insa expressing cells. Adapted 
from Pisharath et al., 2007.  
 22 
1.5. Objectives of this work 
 In chapter two we proposed to identify histological and microarchitecture 
alterations in the long bones of diabetic mice model Ins2+/akita and provide some 
evidence towards identifying the molecular players regulating these changes. 
 In chapter three we aimed to test the effects of vitamin D, vitamin D analogs and 
calcimimetics in fin regeneration and mineralization under diabetic conditions in 
a transgenic zebrafish model of diabetes. 
 In chapter four we focused in understanding the role of paralogs genes of insulin 
in human, mouse and zebrafish, especially if they can also regulate glucose as 
the ancestral gene. Also in this chapter we proposed to investigate if 
extrapancreatic expression of both INS and INS-IGF2 can occur, mimicking 
pancreatic INS action. 
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2.1. Abstract 
Type 1 diabetes mellitus (T1DM) is related to several cartilage and bone 
alterations including growth retardation, increased fracture risk and bone loss. 
Accumulation of advanced glycation end products (AGEs), diminished insulin 
signaling, imbalance in calcitropic hormone levels, and leptin deficiency has been 
identified as possible causes for these alterations. To determine the effect of long term 
diabetes on bone we used adult and aging Ins2+/akita mice that develops T1DM of 5 
weeks after birth. Both Ins2+/akita and WT mice at 4, 6 and 12 months were used to 
assess bone parameters such as femur length, growth plate thickness and number of 
mature and pre-apoptotic chondrocytes. In addition, bone microarchitecture of the 
cortical and trabecular regions was measured by microCT and gene expression of 
Adamst-5, ColII, Igf1, Runx2 and Oc was quantified by qRT-PCR. Ins2+/akita mice 
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showed a decreased longitudinal growth of the femur that was related to decreased 
growth plate thickness, reduced number of chondrocytes and to a higher number of pre-
apoptotic cells. These changes were associated with increased expression of Adamst-5, 
suggesting higher cartilage degradation, and with low expression of Igf1 and ColII that 
influence cartilage matrix formation. Ins2+/akita bone changes were characterized by low 
cortical bone area (Ct.Ar) but higher trabecular bone volume (BV/TV) and to reduced 
gene expression of Oc and Runx2. We suggest that Ins2+/akita mice bone phenotype is 
caused by reduced bone formation and even more reduced bone resorption due to leptin 
and insulin deficiency. 
Keywords: bone; cartilage; diabetes; insulin; leptin.  
2.2. Introduction 
The global prevalence of type 1 diabetes mellitus (T1DM) has been  increasing 
at a rate of 2-5% a year [5] leading to an increase in diabetes related pathologies, 
including bone disorders. T1DM was previously shown to induce alterations in cartilage 
[27,28,31,77,78] and bone loss [27,28,30,35,37,60,79,80], associated to different factors 
like increased glucose serum concentration and reduced insulin secretion by the β-cells, 
inflammation and altered gene expression. Advanced glycation end products (AGEs) 
are proteins or lipids that are formed in hyperglycemic environments. Since their 
cumulative effects increase with age AGEs represent a key player in vascular disease 
associated to diabetes  [81,82]. In addition to affecting the vascular system, AGEs are 
involved in an increase of inflammatory activity and associated to a decreased bone 
formation due  to osteoblastic apoptosis and decreased osteoblast proliferation 
[29,51,52,83] or increased osteoclastic activation [56], and chondrocyte apoptosis in 
cartilage [29,84]. The receptor for AGEs (RAGE) seems to be the molecular 
intervenient that activates the pathways leading to oxidative stress and inflammation 
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[54,85] including in bone since osteoblasts, osteoclasts and chondrocytes express 
RAGE [53,86]. Hypoinsulinemia present in T1DM can also affect bone metabolism 
since insulin signaling in osteoblasts was found to regulate bone resorption by 
activating osteoclasts activity [47], releasing undercarboxylated osteocalcin to the blood 
stream, which in turn affects glucose homeostasis by signaling insulin secretion in β-
cells and others insulin sensitive tissues [43]. This relationship between bone and 
insulin was demonstrated when Ob-IR mice, lacking the insulin receptor (IR) only in 
osteoblasts, became glucose intolerant [47]. T1DM patients and mice models face a 
rapid weight loss during the onset of the disease [27,28,78,80,87], that persists if not 
treated, creating a state similar to the observed by accelerated fastening, that result in 
loss of fat and proteins. Weight loss has been associated with low bone mass [88], but 
interestingly only a decrease in  fat mass was found to be correlated with decreased 
bone mineral density (BMD) and not lean mass or total body weight [89–91]. This close 
relationship between fat and bone seems to be explained by the fact that adipocytes 
secrete leptin. Accordingly, both the leptin knockout (KO) mice ob/ob and the leptin 
receptor KO db/db mice have impaired bone formation, exhibiting a normal or 
decreased cortical bone volume (BV/TV) although presenting a higher trabecular 
BV/TV [65,66]. It was then postulated that leptin binding to its receptors in the 
hypothalamus increases the expression of noradrenaline activating β2-adrenergic 
receptors pathway in osteoblasts, inhibiting bone formation and increasing the 
expression of RANKL, promoting the differentiation and proliferation of osteoclasts 
[62,92,93]. These findings were then supported by the results of β2-adrenergic receptor 
KO mice (Adrb2-/-), that exhibit an increase in trabecular bone at the age of 6 months 
[92]. It has been proposed that peripherally leptin promotes osteoblast proliferation 
through leptin receptor signaling [94,95] and, more recently, Turner and colleagues [65] 
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proposed that peripheral leptin induces bone formation and resorption and that it 
represents the main route of action of leptin in bone. Food intake is correlated with high 
levels of leptin and fasting periods are associated with low levels of leptin as previously 
observed in fasting mice and in anorexia nervosa [96,97]. Devlin et al. [96], performing 
experiments with mice under caloric restriction (CR) from 3 to 12 weeks of age, not 
only correlated leptin levels with CR, but also with low cancellous BV/TV and low 
cortical area, assuming that CR in juvenile mice under a fast period of growth lead to 
bone loss. But unexpected results were observed in the 6 months mice after a period of 
CR of 10 weeks [98], that  presented low cortical mass, but higher trabecular BV/TV in 
the vertebra and unchanged  trabecular BV/TV in the femur. In our study we 
hypothesized that inflammation together with leptin and insulin deficiency could be the 
principal causes involved in cartilage and bone phenotype of Ins2+/akita.  
2.3. Materials and Methods 
2.3.1. Mouse models 
Wild type C57BL/6 and Ins2+/akita (C57BL/6 background) mice at 4, 6 and 12 
months were used to perform the experimental procedures. Diabetes was monitored by 
blood glucose measurements using a Glucose Assay Kit (Free Style Precision, Abbott 
Laboratories, Illinois, USA) and only Ins2+/akita mice with glucose values >300 mg/dl 
were used in this experiment. All animal manipulations were conducted in accordance 
with principles and procedures followed the guidelines from the Federation of 
Laboratory Animal Science Associations (FELASA). Age matched male wildtype mice 
were purchased from Jackson Laboratory (Bar Harbor, Maine). All mice were kept on a 
light/dark (12h/12h) cycle at 23ºC, and received food (standard lab chow) and water ad 
libitum. 
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2.3.2. Total RNA isolation  
Left femur and tibia were isolated, cleaned from adhering tissues then snap-
frozen in liquid nitrogen. Frozen bones were crushed using a mortar and pestle and 
RNA extracted with the Isol-RNA Lysis Reagent 5 PRIME® (Hilden, Deutschland) 
according to manufacturer’s protocol. RNA integrity was verified using ExperionTM 
RNA Analysis Kit (BIO-RAD, Hercules, CA, USA).  
2.3.3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
Reverse transcription was performed using Moloney Murine Leukemia Virus 
Reverse Transcriptase (M-MLV RT) (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. Using iQ™ SYBR® Green Supermix (Life 
Technologies), qRT-PCR was performed on an CFX96 Touch™ Real-Time PCR 
Detection System (BIO-RAD, Hercules, CA, USA) 45 cycles 15 sec. for annealing and 
30 sec. for amplification. All gene expression data were normalized against 
hypoxanthine phosphoribosyltransferase 1 (Hrpt1).  
2.3.4. Bone histology and histomorphometry 
The right tibias were fixed in 4% paraformaldehyde, (pH 7.4 in PBS), and 
decalcified in 10% EDTA/TRIS-HCl (pH 7.4) for 15 days, then  transferred to 70% 
EtOH and processed for dehydration and infiltration on a routine overnight processing 
schedule. Samples were then embedded in paraffin and sections with 6 µm prepared in a 
microtome. Before staining, sections were deparaffinized in Xylene and dehydrated in 
an increasing gradient of EtOH. Sections were stained with safranin O, fast green and 
Mayer´s hematoxylin [99]. 
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2.3.5. Growth plate measurements  
For measurement of the growth plate (GP) thickness, 8 to 10 measurements were 
performed, separated by 0,05 mm of distance per GP. 5 animals for each group were 
used and 3 consecutive histological sections per tibia were analyzed. Proliferative 
chondrocytes were identified according to its morphology and position in the growth 
plate. 
2.3.6. Immunohistochemistry  
Sections were processed as described above. After deparaffination and 
hydration, we performed heat mediated epitope retrieval for 25 min in tris-EDTA pH9 
buffer and hyaluronidase (Sigma H3506) treatment for 30 min. Sections were then 
incubated for 30 min. with blocking buffer (Goat serum and BSA) to block unspecific 
binding sites. Sections were incubated overnight at 4 °C with rabbit polyclonal Anti-
Caspase-3 diluted in PBS 1:100 (ab13847, ABCAM, Cambridge, UK). Slides were then 
incubated in 0.3% H2O2 in PBS with 0.1% Triton X-100 for 15 min. The secondary 
antibody, anti-rabbit IgG – peroxidase (Sigma Aldrich) was applied diluted 1:100 in 
PBS and incubated for 90 min at room temperature. The signal was detected by 
incubating the sections for 4 min in a 0.1% 3,3′-diaminobenzidine (DAB) substrate and 
0.02% hydrogen peroxide solution. The sections were counterstained with Mayer’s 
hematoxylin.  
2.3.7. Detection of apoptosis 
Total number of Caspase 3 positive proliferative and hypertrophic cells was 
counted and hematoxylin stained cells were used as negative control for pre-apoptotic 
cells. From each animal tested at least 3 sections from each femur separated by 25 µm, 
were counted and the percentage of apoptotic cells in growth plate calculated. Cells 
were counted using the cell counter plug-in of imagej software. 
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2.3.8. Micro-computed Tomography (CT) analysis  
Three femurs from each time point and genotype were scanned using a Bruker 
microCT Skyscan™ CT 1072 scanner (Kontich, Belgium) with an accelerated voltage 
of 50 kV and a current source of 197 uA at 5.1µm of pixel size. Measurements in the 
trabecular region were made in the distal epiphysis of the femur defined at 0.255mm 
under the growth plate extending 1mm (200 layers) toward to diaphysis, and excluding 
the outer cortical shell. Quantitative parameters were obtaining by the Skyscan™ CT-
analyzer software for each region of interest. The thickness of the cortical bone was 
measured through the images of DataViewer software taken from the distal femoral 
methaphysis and all measurements were done using the ImageJ software.  
2.3.9. Statistical analysis 
All statistical analyses were performed using Stata Statistical Software data 
analysis and data was evaluated using the one-way ANOVA followed by Bonferroni 
multiple comparisons test with p˂0.05 considered statistically significant. Results are 
presented as means ± standard deviation of the mean (SD). 
2.4. Results  
2.4.1. T1DM reduces femur length and body weight in Ins2+/akita 
Diabetes in Ins2+/akita mice caused a reduction in femur length and body weight 
at all 3 analyzed age stages. Reduction in femur length were found to be of 5.35%, 
5.34% and 3.8%, at 4, 6, and 12 months respectively (figure 10.B), the differences being 
statistically significant with p<0.001. This reduction was also observed in body weight 
of Ins2+/akita, with differences of 27.06%, 26.16% and 26.92%, at 4, 6, and 12 months 
respectively, with p<0.05 (figure 10.C).  
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Figure 11  A) X-ray analysis of Ins2+/akita and WT mice femurs at 4, 6 and 12 months; B) Ins2+/akita 
Femur length is  highly significant smaller than WT at 4, 6 and 12 months, demonstrating that type 1 
diabetes mellitus is related to growth retardation. is li  C All body weight of Ins2+/akita is constantly 
significantly reduced than WT at 4, 6 and 12 months, caused by the impaired glucose homeostasis leading 
to activation of alternative pathways degrading fatty acids and  proteins from soft tissues leading to 
weight lost. *p<0.05, **p<0.001. 
 
2.4.2. Growth plate thickness is reduced in Ins2+/akita 
Potential alterations in growth plate structure will impair longitudinal bone 
growth so we investigated if growth plate of Ins2+/akita could be affected. Growth plate 
measurements showed that at 4 and 6 months the thickness was reduced, but at 12 
months of age only a trend for reduction was observed (figure 11.B). Taking into 
account that it is during the proliferative phase of chondrocytes that bone lengthening 
occurs, we counted the total number of proliferative chondrocytes and significant 
differences were observed at 4 and 6 months in Ins2+/akita compared to WT, showing a 
reduction in the number of proliferative chondrocytes (figure 11.C). No differences 
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were observed at 12 months, a result which is in agreement with growth plate thickness 
measurements. To determine if the number of hypertrophic chondrocytes was altered, 
we performed an immunohistochemical detection of caspase 3 with the objective of 
identifying pre-apoptotic cells. The total number of chondrocytes in growth plate was 
determined by counting the cells under the microscope and significant differences were 
observed at 4 months, with the group of Ins2+/akita having a higher percentage of pre-
apoptotic cells (figure 12.B). 
.  
Figure 12. A) Growth plate thickness of Ins2+/akita mice and WT. Reduced number of proliferative 
chondrocytes leaded to thinner growth plates and to longitudinal bone growth, black arrows represent 
average of growth plate thickness of WT; B) and C) growth plate thickness and number of proliferative 
chondrocytes are significantly reduced at 4 and 6 months in Ins2+/akita but not at 12 months.  
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Figure 13. A) Evaluation of pre-apoptotic cells by Immunohistochemistry  in growth plate, black arrow 
caspase 3 positive cells, yellow arrow negative cells; B) Ins2+/akita showed increased number of pre-
apoptotic cells in growth plate than WT significant differences *p<0.05. 
 
2.4.3. Ins2+/akita have reduced cortical area and higher trabecular bone 
volume at 4, 6 at 12 months  
Total area (Tt.Ar) of cortical bone in Ins2+/akita was found to be reduced by 32% 
at 4 months, 16% at 6 months and 25% at 12 months of age. These differences were 
significant for all ages analyzed (p˂0.05) (Table 1). The reduction in cortical bone was 
principally due to a substantial decrease in cortical area (Ct.Ar), of 53% at 4 months, 
35% at 6 months and 25% at 12 months, with all results highly significant compared to 
WT controls (p<0,001) (Table 1 and Figure 13.B). This decline in cortical bone 
observed in the diabetic mice was confirmed by a decrease in the cortical area fraction 
(Ct.Ar/Tt.Ar), cortical thickness (Ct.Th) and periosteal perimeter (Ps.Pm) (p<0.05) 
(Table 1). Although not significantly different, the marrow area (Ma.Ar), showed a 
reduction in area at all ages. A significant reduction was found in the endocortical 
perimeter (Ec.Pm) (p<0.05) at 12 months (Table 1). Cortical bone parameters were 
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relatively constant from 4 to 12 months in Ins2+/akita. Diabetic mice did not show any 
signs of recovery or aggravation of the low cortical area with aging. 
 
Figure 14. A) Histological sections of the cortical proximal diaphyseal, mid and distal diaphyseal shaft of 
the tibia and microCT images of the cortical diaphyseal distal shaft of the femur of Ins2+/akita and WT 
mice of 4, 6 and 12 months; Diabetes induced cortical bone loss and significant differences could be 
found in Tt.Ar, Ct.Ar, Ct.Ar/Tt.Ar, Ct.Th, Ps.Pm. bone volume reduction occurred by the decline 
periosteum perimeter suggesting reduced bone formation; B)  Ins2+/akita mice has highly significant reduce 
cortical bone area when compared to WT mice at 4, 6 and 12 months,;  **p<0.001. 
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Trabecular bone parameters showed opposite results from those found in cortical bone. 
Differences in bone volume relative to trabecular volume (BV/TV) in Ins2+/akita were 
found to be highly significant at 4 months (p<0.001) with an increase of 45%, an 
increase of 46% (p<0,05) at 6 months, and an increase of 30% at 12 months (Table 1 
and Figure 14.B).  
Table 1.   Femur morphometry data of trabecular distal region and of metaphysis distal cortical region. 
 
BV/TV Bone volume %; BS/TV Bone surface density Ratio mm2/mm3; BS/BV Specific bone surface 
mm2/mm3; SMI Structure model index; Tb.N Trabecular number 1/mm; Tb.Th Trabecular thickness 
mm; Tb.Sp Trabecular separation  mm; Tt.Ar Total area inside the periosteal envelope mm2; Ct.Ar 
Cortical bone area mm; Ma.Ar Medullary area mm2; Ct.Ar/Tt.Ar Cortical area fraction %; Ct.Th Average 
cortical thickness mm; Ps.Pm Periosteal perimeter mm; Ec.Pm Endocortical perimeter mm *p<0.05, 
**p<0.001.  
 
Differences were also observed on the increased bone surface relative to 
trabecular volume (BS/TV) at 4 (p<0,001), 6 (p<0.001) and 12 months (p<0.05).  
Higher BV/TV values in Ins2+/akita were due to a significant increase in the number of 
trabeculae (Tb.N), that was of 45% at 4 months (p<0.001), 52 % at 6 months (p<0.05) 
and 43% at 12 months, and not due to the size of the trabeculae, since no differences 
were observed in the specific bone surface (BS/BV) or in the trabecular thickness 
 4 months 6 months 12 months 
Trabecular 
Akita 
n = 3 
WT 
n = 3 
Akita 
n = 3 
WT 
n = 3 
Akita 
n = 3 
WT 
n = 3 
BV/TV (%) 33,13* ± 3,53 18,34 ± 0,772 14,86* ± 0,370 8,01 ± 3,420 10,18 ± 1,334 7,13 ± 1,984 
BS/TV (mm2/mm3) 0,022** ± 0,001 0,013 ± 0,000 0,012** ± 0,001 0,006 ± 0,002 0,008* ± 0,001 0,005 ± 0,001 
BS/BV (mm2/mm3) 0,068 ± 0,004 0,073 ± 0,003 0,082 ± 0,002 0,082 ± 0,010 0,083 ± 0,006 0,073 ± 0,005 
SMI 1,82* ± 0,182 2,27 ± 0,070 2,48 ± 0,107 2,69 ± 0,227 2,26 ± 0,033 2,65 ± 0,231 
Tb.N (1/mm) 
0,0060** ± 
0,0005 
0,0033 ± 
0,0001 
0,0031* ± 0,0002 0,0015 ± 0,0006 0,0021 ± 0,0002 0,0012 ± 0,0003 
Tb.Th (mm) 55,29 ± 1,724 55,94 ± 2,391 48,11 ± 1,304 52,93 ± 5,632 47,91* ± 3,041 59,40 ± 1,020 
Tb.Sp (mm) 95,79** ± 5,847 
160,58 ± 
7,572 
148,40** ± 1,251 234,20 ± 21,043 200,52** ± 3,991 272,14 ± 23,111 
Cortical       
Tt.Ar (mm2) 1,91** ± 0,180 2,52 ± 0,242 1,97 ± 0,04 2,30 ± 0,06 2,08* ± 0,144 2,60 ± 0,135 
Ct.Ar (mm2) 0,76** ± 0,065 1,16 ± 0,076 0,72** ± 0,05 0,97 ± 0,03 0,78** ± 0,060 1,11 ± 0,009 
Ma.Ar  (mm2) 1,14 ± 0,12 1,36 ± 0,18 1,24 ± 0,01 1,33 ± 0,08 1,30 ± 0,11 1,49 ± 0,14 
Ct.Ar/Tt.Ar (%) 0,40* ± 0,015 0,46 ± 0,020 0,37** ± 0,02 0,44 ± 0,02 0,37* ± 0,020 0,43 ± 0,025 
Ct.Th (mm) 0,15** ± 0,014 0,20 ± 0,010 0,13** ± 0,01 0,17 ± 0,01 0,15* ± 0,005 0,18 ± 0,013 
Ps.Pm (mm) 5,14* ± 0,323 6,04 ± 0,394 5,32* ± 0,07 6,03 ± 0,09 5,36* ± 0,212 6,23 ± 0,292 
Ec.Pm (mm) 4,07 ± 0,243 4,55 ± 0,299 4,33 ± 0,01 4,75 ± 0,10 4,31* ± 0,177 5,05 ± 0,527 
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(Tb.Th) (Table 1). In Ins2+/akita the high Tb.N led to a highly significant (p<0.001) 
reduction in trabecular separation (Tb.Sp) parameters in all 3 time points analyzed 
(Table 1). 
 
Figure 15. A) Histological sections of the proximal mid-epiphysis of the tibia and MicroCT images of the 
distal mid-epiphysis of femur of Ins2+/akita and WT mice of 4, 6 and 12 months and significant differences 
could be seen in BV/TV, BS/TV, Tb.N and Tb.Sp bone parameters. The higher bone volume observed in 
Ins2+/akita trabeculae is explained by the increase in trabeculae number and not trabeculae thickness or 
size. These results also suggest reduced bone resorption; B)  Ins2+/akita mice has significant increase in 
trabecular bone volume (BV/TV) when compared to WT mice at 4, 6  and a trend of increase at 12 
months *p<0.05, **p<0.001. 
 
2.4.3. Expression of cartilage and bone marker genes is altered in Ins2+/akita 
To determine the mechanisms leading to alterations in the cartilage in Ins2+/akita 
we examined the expression levels of Adamst-5, that cleaves proteoglycans, and col2, 
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the most abundant protein in cartilage. Adamst-5 was found to be overexpressed at all 
time points in Ins2+/akita being highly expressed at 4 and 12 months (p<0.001) and also 
significantly upregulated at 6 months (p<0.05) (Figure 16.A). Col2 expression was 
found to be downregulated at both 4 and 6 months (p<0.05) compared to WT (Figure 
16.B). To determine if growth factors were also affected, Igf1 gene expression levels 
were found to be downregulated at 6 months (p<0.05) and highly downregulated at 4 at 
12 months (p<0.001) (Figure 16.C). Expression levels of Runx2, one of the main 
transcription factor involved in osteoblast differentiation, was found to be significantly 
reduced at 4 and 6 months (p<0.05) in Ins2+/akita (Figure 16.E) while the marker of 
mature osteoblasts osteocalcin (OC or BGP) was signidficantly upregulated at 4 months 
but not at later stages. 
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Figure 16.  Diabetes in Ins2+/akita induced changes in mRNA gene expression in cartilage and bone; A) 
Adamst-5 expression is increased at all ages in Ins2+/akita suggesting higher cartilage degradation; B) Col2 
expression is reduced at 4 and 6 months in Ins2+/akita being in accordance with the reduced cartilage matrix 
area of growth plate; C. Igf1 expression is reduced at all ages in Ins2+/akita explaining in part the growth 
retardation phenotype; D) and E) Oc and Runx2 expression is reduced at 4 months and at 4 and 6 months 
Ins2+/akita respectively, suggesting reduced bone growth. *p<0.05, **p<0.001.  
 
2.1.5. Discussion 
T1DM is related to bone growth retardation in puberty [100,101] and increased 
risk of fracture throughout life, leading to increased morbidity and mortality [102]. 
Increased bone porosity and smaller cortical area are the principal causes for the 
observed decrease in biomechanical properties, as previously reported for type 2 
diabetic postmenopausal women [103]. In the present study, growth retardation could 
OC 
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also be observed in Ins2+/akita mice, reflected by a decreased length of the femurs when 
compared to WT mice at all time points. Similar results were found in Ins2+/akita at 10 
weeks [27], in streptozotocin induced diabetic mice and rats [27,28,80], in CR mice 
[96,98], in ob/ob and leptin receptor db/db mutants [62,63,65]. In our work, impaired 
bone growth in length could be explained by a reduction in growth plate thickness of 
Ins2+/akita mice at 4 and 6 months and increased number of pre-apoptotic chondrocytes 
in growth plate at 4 months that reflect a lower metabolic activity of the cartilage and 
translates in reduced bone growth. Similar results were observed in diabetic rodents and 
in CR mice [27,79,96] demonstrating a direct relation between diabetes and impairment 
of long bone growth.  Reduction in growth plate thickness could also be explained by a 
decrease in the number of proliferative chondrocytes and downregulation of Col2, also 
observed in Ins2+/akita at 10 weeks [27]. Increased bone inflammation has been 
associated with osteoblast death, that have been related to bone marrow inflammatory 
events [57] and specially by increasing pro-apoptotic and pro-inflammatory cytokines in 
bone environment [37]. One of those well-defined cytokines is tumor necrosis factor α 
(TNFα) [104,105] which has been associated with upregulation of metalloproteinases 
including Adamst-5 [106]. Accordingly, this enzyme was found to be highly expressed 
in our study, likely contributing to higher cartilage degradation. Our results also showed 
low expression levels of Igf-1 in Ins2+/akita at all time points. Reduced circulating Igf-1 
concentrations have been associated with reduced linear growth [107], cartilage 
degradation, chondrocytic and osteoblastic proliferation [108]. Serum Igf-1 was also 
found to be reduced in CR mice [96,98] caused by impaired growth hormone signaling 
[109]. These results suggest that a decreased Igf signaling might be involved in the 
reduction of bone quality parameters observed in diabetics. Diabetes has been 
associated to leptin deficiency [38,110,111], and leptin treated mice were shown to have 
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induced chondrocyte proliferation and increased growth plate [65,95]. In diabetes 
intracellular glucose starvation mimics starvation periods and, not surprisingly, the 
results of growth retardation showed by Ins2+/akita resembles the CR mice phenotype. 
Our results on the microarchitecture of the distal femur, showing low cortical and high 
trabecular bone also resembles the results observed in CR mice [98], Adrb2-/- [112] and 
ob/ob [66] at 6 months, Adrb2-/- mice at 4 months [64] and in ob/ob at 3 and 6 months 
[65,113] in the vertebrae. Reduced insulin signaling in adipocytes and weight loss in 
diabetes leads to low expression of leptin [60] and what Ins2+/akita as in common that 
could explain this similarities with previous models is leptin deficiency. To explain the 
mosaic phenotype, Hamrick et al. (2008) [98] suggested that under caloric restriction 
there is a leptin deficiency and increased neuropeptide Y signaling  leading to reduced 
cortical bone. Baldock et al [114] reported an increase in cortical bone volume in Y2 
receptor KO mice but double Y2 receptor and leptin KO mice had a cortical bone 
volume similar to the presented by leptin KO mice, meaning that cortical bone growth 
in leptin deficient mouse models cannot be explained only by this pathway. In the 
trabecular region, neither Coe et al. [27], with Ins2+/akita mice at 10 weeks, nor Devlin et 
al. [96] using CR mice at 12 weeks, found higher trabecular bone volume, but instead 
there was a reduction of trabecular bone observed in those reports. These results are 
consistent with the fact that high trabecular bone volume could only be observed in 
Adrb2-/- mice at 6 months (58) and, more recently, at 4 months [64,92]. In our study we 
could detect this increase in Ins2+/akita starting at 4 months. It was shown by Ducy et al. 
[66] that both ob/ob and db/db KO mice at 6 months had increased trabecular BV/TV 
both in vertebrae. To explain the high trabecular volume and low cortical bone volume, 
conflicting theories have been presented, emphasizing in one side the neuroendocrine 
role of leptin [113,115] in inhibiting bone formation and stimulating bone resorption or, 
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on the other hand, suggesting a higher importance of the stimulatory effect of leptin in 
bone peripherally [68]. Turner et al. [65] have proposed that leptin can influence bone 
by acting centrally and peripherally and in both cases leptin induces bone formation and 
resorption, concluding that regulation was predominantly made by direct signaling on 
both osteoblastic and osteoclastic lineages. Lower osteocalcin and even lower cross-
linked C-telopeptide serum levels in leptin KO ob/ob and in leptin receptor KO db/db 
mice was associated with low bone formation and low bone resorption. These 
conclusions led to the assumption that increased bone volume in the trabecular bone of 
the vertebrae was due to reduced bone formation but even further reduced bone 
resorption. Turner and collaborators [65] also raised the theory that the regulation of 
osteoclasts by osteoblasts is merely speculative, questioning the β2-adrenergic receptor 
pathway by which osteoclasts are indirectly regulated. This hypothesis immediately 
raises the question: if leptin signaling in the hypothalamus activating the β2-adrenergic 
pathway in osteoblasts is not the primary route of action in increasing bone resorption 
by osteoclasts, so why mutant Adrb2-/- present such a pronounced bone phenotype? It 
was expected that a direct action of leptin in bone cells could stabilize normal bone 
formation and resorption, or maybe this pathway is only active later in life as mentioned 
above. Again Turner and collaborators [65] proposed an interesting model to explain the 
reduced cortical bone and increased trabecular bone phenotype. Since leptin acts over 
chondrocytes, osteoblasts and osteoclasts to enhance their number and/activity, changes 
in bone mass and architecture are dependent on local prevalence of osteoblasts and 
osteoclasts. So, in the periosteum of the cortical bone, where we have an increased 
presence of osteoblasts and reduced presence of osteoclasts, it is expected a reduced 
bone formation. In trabecular bone, the reduction in bone resorption can preserve 
trabecular number, providing a template for addition of new bone. This theory is in 
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agreement with our results, since trabecular bone surface (BS/TV) and trabecular 
number (Tb.N) in Ins2+/akita are always significantly increased at all time points, and 
expression of genes associated with bone formation (Oc and Runx2) showed to be 
downregulated, principally at 4 months, when we could observe more pronounced 
differences by morphometry in trabecular and cortical bone. To the best of our 
knowledge, this theory seems to be the best explanation to the local increases of 
trabecular bone and decreases in cortical bone mass. Other cause for the presumable 
reduced bone formation and resorption rate expressed by our results, is the fact that 
insulin signaling in osteoblasts have been associated to increased osteoblast and 
osteoclast activity promoting both bone formation and resorption [43]. Fulzele et al.  
[116] in their work with mice lacking insulin receptor specifically in osteoblasts, Ob-IR, 
could see reduced numbers of osteoblasts, low bone formation rate and low serum CTx. 
Although they presented signs of reduced bone formation and resorption, Ob-IR showed 
reduced BV/TV and Tb.N in the trabecular region at 3 and 6 weeks. But at 3 months 
Ob-IR presented only a trend of reduced BV/TV and Tb.N leading us to question what 
would be the trabecular phenotype of older Ob-IR mice. Nevertheless, Ins2Akita is insulin 
deficient and according to previous studies leptin deficient [117,118], two antiresorptive 
conditions, and this double disorder may explain why in our study diabetic mutants 
presented such marked differences, where in the trabecular region of the Ins2+/akita at 4 
months bone volume was almost two times higher. Finally, we have for the first time 
identified a clear effect of diabetes in the microarchitecture of the long bones in the 
T1DM Ins2+/Akita model, with a mosaic pattern most likely caused by presumable leptin 
deficiency, lack of insulin signaling or both. 
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3.1. Abstract 
Bone changes related to diabetes have been well stablished, but few strategies 
have been developed to prevent this growing health problem. In our work we proposed 
to understand the effects calcitriol, a vitamin D analog and a calcimimetic in fin 
mineralization and regeneration in a zebrafish model of diabetes. We exposed diabetic 
transgenic Tg(ins:nfsb-mcherry) zebrafish to calcitriol, paricalcitol, cinacalcet and 
caudal fins were amputated to assess the effects on regeneration. Caudal fin mineralized 
and regenerated areas were quantified by in vivo alizarin red staining. Quantitative real 
time PCR was performed using RNA from the vertebral column for determining 
expression levels of parathyroid hormone receptor (pthr), vitamin D receptor (vdr), 
insulin receptor a (insra) runt-related transcription factor 2 (runx2), oxterix (osx), 
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osteocalcin (oc), insulin a (insa) and insulin b (insb). Increased regenerated and 
mineralized areas could be found in diabetic fish treated with cinacalcet and paricalcitol, 
when compared to non-treated diabetic group. Gene expression analysis suggested a 
trend of decreased pthr expression in all three treated groups, while runx2, insa, insb 
were found to be upregulated and a trend of increase was observed for osx and oc in 
diabetic groups treated with cinacalcet and paricalcitol. insra and vdr expression was 
found to be upregulated in diabetics treated with cinacalcet. Increased mineralization 
and regeneration in diabetic zebrafish treated with cinacalcet and paricalcitol can be 
explained by a decrease in circulating parathyroid hormone, reducing bone resorption 
and increased osteoblastic differentiation, indicating the pro-osteogenic potential of the 
drugs tested.  
Diabetes; bone; zebrafish; mineralization; vitamin D analogs; calcimimetics. 
3.2. Introduction 
Prevalence of diabetes mellitus worldwide was estimated to be of 135 million in 
1995 and is predicted to be of 300 million in the year 2025 [119] leading to an increase 
in patients living with the risk of developing diabetes-related complications [120]. 
Diabetes has been strongly associated with development of bone fractures, that begins 
in childhood and extends throughout life, leading to morbidity and mortality [121,122]. 
Calcitriol (1,25-dihydroxyvitamin D3 - VitD) deficiency is common in chronic kidney 
disease (CKD) patients, leading to secondary hyperparathyroidism (SH) [123] and 
particularly those with diabetes undergoing  dialysis have been correlated to low 25-
hydroxyvitamin D in the serum due to lack of suprarenal gland activity [122]. 
Parathyroid hormone (PTH) stimulates bone resorption directly by activating PTH 
receptors in mesenchymal cells of the osteoblast lineage and indirectly by increasing 
differentiation and function of osteoclasts [124]. Bone loss and increased fracture risk is 
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among the complications presented by CKD patients with SH [122,125,126] and also 
seen in rodent models [127,128]. VitD, the vitamin D analog paricalcitol [129] and the 
calcimimetic cinacalcet [130] have been used for the treatment of SH in CKD patients 
with beneficial effects in lowering PTH values and also in increasing bone mass 
[122,125,126]. Paricalcitol, by activating selectively vitamin D receptor (VDR) 
[131,132], and cinacalcet, activating calcium sensing receptor [131,133] in parathyroid, 
have been shown to be more efficient and fast in normalizing PTH levels and also in 
reducing circulating bone turnover markers than VitD [134,135]. Zebrafish models of 
human diseases have been well established, spanning a wide range of human 
pathologies including genetic disorders and physiological processes that are known to 
be highly conserved throughout vertebrate evolution [136]. Recently it was 
demonstrated, under type 1 diabetic conditions, that fin regeneration was impaired in 
zebrafish with reduced cell proliferation and increased cell apoptosis [33]. We 
conducted experimental trials to understand if VitD, paricalcitol and cinacalcet, could 
have beneficial effects on caudal fin regeneration and bone mineralization in adult 
zebrafish and in operculum development of larvae under type 1 diabetic conditions. To 
test this hypothesis we used the transgenic Tg(ins:nfsb-mcherry) zebrafish that after 
exposed to the pro-drug metronidazole becomes hyperglycemic and hipoinsulinemic 
due to beta-cell ablation, leading to a transient state of diabetes during 10 to 15 days 
prior to beta-cell regeneration [74,76]. To understand if vitamin D analogs and 
calcimimetics could have positive effects on bone, during a diabetic window period, fin 
regeneration and bone mineralization areas were quantified and expression analysis of 
bone and vitamin D metabolism markers was investigated. 
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3.3. Methods 
3.3.1. Zebrafish strains and maintenance 
 The trangenic Tg(ins:nfsb-mcherry) zebrafish line used in our experiment was 
kindly given by the  Laboratory of Molecular Biology and Genetic Engineering, GIGA 
Research, Liege, Belgium.  Transgenic zebrafish were maintained in a recirculating 
water system (Tecniplast, Buguggiate, Italy). All manipulations were performed by 
licensed researchers and conducted in accordance with principles and procedures 
following the guidelines from the Federation of Laboratory Animal Science 
Associations (FELASA) and in accordance with the EU and national regulations. The 
Tg(ins:nfsb-mcherry) line generated by Pisharat et al. [74] with a Tübingen AB 
background, contains a construct downstream to the promoter region of the insa gene of 
the gene nfsB of E. coli and the florescent protein mCherry. This bacterial gene encodes 
a nitroreductase (NTR) enzyme, that converts pro-drugs such as metranidazole (MET; 
Sigma-Aldrich, St. Louis, USA) to cytotoxins. By observation of loss mCherry 
florescence it is possible to visualize MET induced beta-cell ablation. 
3.3.2. Procedures 
Diabetes induction: Larvae of 15 days and Male and female adults with 1 year 
old Tg(ins:nfsb-mcherry) zebrafish were anesthetized with tricaine methanesulfonate 
(Sigma-Aldrich, St. Louis, USA) [137] and exposed to MET either by bath or through 
intraperitoneal (IP) injection at the concentration of 0,05M dissolved in citrate buffer 
(0,05M). Paricalcitol, cinacalcet and VitD treatments: 72 hours post treatment (hpt) with 
MET, transgenic zebrafish loss florescence due to beta-cell ablation, as observed by 
Pisharath et al. [74]. To understand if treatments could induce bone alterations in 
diabetic conditions, groups of 125 larvae and 125 adults were divided and exposed by 
immersion or IP injection, respectively, of VitD (0,001μg/ml) (calcitriol, Sigma-
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Aldrich), cinacalcet (0,05μg/ml) (mimpara®, Amgen Europe B.V., Breda, Netherlands), 
paricalcitol (0,001μg/ml) (zemplar®, Abbott Laboratories, Illinois, USA) or vehicle 
(citrate buffer 0,05M) for the control groups of non-diabetic and diabetics. Fin 
amputation: After the IP injections with treatments or vehicle, the caudal fins of treated 
adults were amputated two segments bellow the bifurcation of the second ray. Both 
larvae and adults were maintained under treatment for 120 hours at 28,5ºC and fed 
twice a day with Artemia nauplii (EG strain, Inve, Belgium). Mineral staining: Larvae 
were fixed with PFA 4% for 1 hour, washed in PBS and stained in 0,01% alizarin red 
for 30 min. Adults were submitted to live staining in alizarin red at a concentration of 
0,01% for 15 min prior to observation. Adult regenerated caudal fins and larval opercula 
were photographed under green florescent light under a microscope for identification of 
the calcified regions. Quantification mineralized area in larvae: Mineralized area of 
opercula stained by alizarin red were measured using image J software. Results were 
normalized by dividing operculum area (OA) by total area of the head (HA). 
Quantification of regenerated and mineralized area of adult fin: Regenerated area was 
determined by dividing regenerated area (REG) by stump width (STU) and mineralized 
area was determined by dividing mineralized area (MIN) by mean ray width and 
divided by REG/STU. All quantifications were done using image J software. Glucose 
tolerance test: To confirm that ablation of beta-cells in Tg(ins:nfsb-mcherry) zebrafish 
led to an increase of glucose blood concentrations, we administrated a solution of 
glucose at a concentration of 0,1 M or vehicle by IP injection, to two groups of adult 
zebrafish after 72 hpt with MET. Blood glucose was monitored at 30, 60, 90, 120, 150, 
180 minutes after IP injection with glucose. The glucose levels were measured in 3 
Tg(ins:nfsb-mcherry) zebrafish treated with MET and vehicle at each time point. 6 μl of 
blood were collected from the caudal aorta, diluted in 2 μl of 2% heparin and rapidly 
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transferred to a blood glucose meter GlucocardTM MX (Arkray A. Menarini 
Diagnostics, Florence, Italy). Total RNA isolation: Vertebral columns were isolated and 
placed in 1ml of Isol-RNA Lysis Reagent (5 PRIME, Hilden, Deutschland) and total 
RNA was purified according to manufacturer’s protocol. RNA quantity and integrity 
was verified using ExperionTM RNA Analysis Kit (BIO-RAD, Hercules, CA, USA). 
Quantitative real-time polymerase chain reaction (qPCR): Reverse transcription of 1 g 
of total RNA was performed using Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Semi quantitative qPCR was performed using iQ™ 
SYBR® Green Supermix (Life Technologies), on an CFX96 Touch™ Real-Time PCR 
Detection System (BIO-RAD, Hercules, CA, USA), conducted for 45 cycles of 5 sec at 
95ºC and 15 sec at 60ºC each. The primer sequences of elongation factor 1alpha (ef1-
alpha), 18S ribosomal rna (18S), runt-related transcription factor 2 (runx2), 
osteocalcin (oc), osterix (osx), parathyroid hormone receptor (pthr),vitamin D receptor 
(vdr),insulin a  (insa), insulin b (insb) and insulin receptor a (insra) are listed in 
supplementary Table 1. All gene expression data were normalized against the average 
of the gene expression levels of housekeeping genes ef1-alfa and 18S. To confirm 
extrapancreatic expression of insa and insb genes, observed by qPCR, a RT-PCR 
reaction was performed and the identity of the amplicons confirmed by sequencing. 
3.4. Results 
To confirm that Tg(ins:nfsb-mcherry) exposed to MET could leed to a state of 
diabetes type I, a glucose tolerance test was performed. We found that glucose 
concentrations in the plasma of fish treated with MET, had significantly higher 
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concentrations than fish treated with vehicle only, with this differences being highly 
significant at 90, 120 ,150 and 180 minutes after IP injection (Figure 16).  
 
Figure 17. Transgenic zebrafish Tg(ins:nfsb-mcherry) 72 hours post induction of diabetes have increased 
blood glucose concentrations at 30, 60, 90, 120, 150, 180 min. after intra-peritoneal  injection with 
glucose *p<0,05; **p<0,001. 
 
 
 
Figure 18. A) Paricalcitol induced operculum mineralization in diabetic larvae; B) 15 day old diabetic 
larvae have reduced operculum mineralized area when compared to non-diabetic, but treatment with 
paricalcitol increased the mineralized area compared to diabetic. 
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An analysis of the mineralized area of the operculum of larvae from the diabetic 
group revealed a significant reduction when compared to non-diabetic. However, the 
operculum mineralized area was significantly increased when diabetic were treated with 
paricalcitol compared to diabetic alone. Diabetic treated with VitD showed an increase 
in mineralization compared to untreated diabetic, although not significantly different 
due to individual variability. Cinacalcet concentrations used in these experiments 
showed to be lethal for diabetic larvae (figure 17.B). Beta-Cell ablation in adults led to a 
statistically significant impairment of fin regeneration in diabetic when compared to 
non-diabetic. Also, the treatment groups with paricalcitol and cinacalcet presented a 
significant increase in regenerated area when compared to diabetic and a trend of 
increased regeneration when compared to non-diabetic (figure 18.B). 
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Figure 19 A. Treatment with paricalcitol and cinacalcet induced fin regeneration and bone mineralization 
in adult diabetic zebrafish; B. Diabetic group had decreased fin regenerated area compared to non-
diabetic and to diabetic treated with paricalcitol and cinacalcet; C. Diabetic group had decreased fin 
mineralized area compared to non-diabetic and to diabetic treated with paricalcitol and cinacalcet. 
 
 The regenerated area of the diabetic group treated with VitD did not present any 
significant differences compared to the other groups. Quantification of the mineralized 
area showed that groups treated with paricalcitol and cinacalcet had no differences when 
compared to non-diabetic, while the diabetic fish showed a significantly reduced 
mineralization when compared to non-diabetic, paricalcitol and cinacalcet treated 
groups, while VitD group showed no differences relative the other groups (figure 18.C).  
Analysis of gene expression showed that VitD, paricalcitol and cinacalcet treated 
groups presented a trend of reduction in the expression of pthr when compared to non-
diabetic and to diabetic fish (figure 19A). The vdr expression, showed a statistically 
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significant increase in the cinacalcet group compared to all other groups (figure 19.B). 
insra expression was found to be significantly down regulated  in all groups (p<0,5) 
compared to non-diabetic, but the cinacalcet group showed a lower reduction in 
expression, with statistically higher values compared to diabetic, paricalcitol and VitD 
treated fish (figure 19.C). osx expression showed a trend of reduction in all treated 
groups compared to non-diabetic but only significant downregulation was found in 
diabetic compared to non-diabetic (figure 19.D). Regarding runx2 a significant 
upregulation could be observed in groups treated with paricalcitol and cinacalcet 
(p<0,05) (figure 19.E). Expression of oc was found to be downregulated in diabetic 
compared to non-diabetic while the remaining groups showed no significant differences. 
Gene expression of insa and insb was found to be upregulated (p<0,001) in both 
paricalcitol and cinacalcet treated fish compared to the other groups (figures 19.G and 
19.H). 
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Figure 20.  RNA gene expression from the vertebral column of diabetic or diabetic with treatments is 
altered in zebrafish; A. Diabetic treated groups presented a trend of reduction in pthr expression; B. 
Diabetic treated with cinacalcet have an increase in vdr expression compared to all the other groups; C. 
All diabetic groups presented a reduction in insr expression with the exception of the group treated with 
cinacalcet; D. Differences could be observed between non-diabetic and diabetic in osx expression, treated 
groups show no differences between untreated groups ; E. Diabetic groups treated with paricalcitol and 
cinacalcet showed an increase in the expression of runx2; F. Diabetic group showed reduced expression 
of oc compared to non-diabetic, and treated groups show no differences relating untreated groups; G. and 
H. Diabetic groups treated with paricalcitol and cinacalcet showed an increase in the expression of both 
insa and insb gene. 
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Figure 21.  Zebrafish can have extrapancreatic expression of both insa and insb. Expression of insa and 
insb could be detected in pancreas/liver, muscle, kidney, and bones from vertebral column and 
cleithrum/operculum.  
 
To demonstrate the extrapancreatic expression of both insa and insb in vertebral 
column, we performed an RT-PCR using cDNA of liver/pancreas, muscle, kidney, 
column and cleithrum/operculum, using the same primers used for qPCR. We observed 
amplification of ins genes in all tissues analyzed (figure 20). This result was further 
confirmed by sequencing of the PCR amplicons that proved to be correspondent to 
insulin a and b isoforms respectively. 
3.5. Discussion  
This study demonstrated that zebrafish is a suitable model for the study of bone 
pathologies related to diabetes. Ablation of beta-cell by exposing Tg(ins:nfsb-mcherry) 
zebrafish to MET, led to loss of mCherry fluorescence in the beta-cells at 72 hpi, as 
described by previous authors [74,76], and caused a significant increase in blood 
glucose , although differences were not so accentuated as previously reported  [74,76]. 
Induction of diabetes in zebrafish caused an impairment in operculum mineralization 
and bone growth in 15 day larvae, similar to growth retardation observed in diabetes 
type 1 patients [138] and diabetes mice models [139]. Treatment with paricalcitol led to 
an increase in the mineralized area more efficiently than VitD. The concentrations used 
of Cinacalcet, same as used in clinic therapies, were found to be toxic in larvae as the 
rate of mortality was of 100% after 24 hours. Regenerated fin area of adults showed an 
increase in the diabetic groups treated with paricalcitol and cinacalcet when compared 
to diabetic group treated with vehicle. Diabetics from the VitD treated group did not 
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present such a marked increase. There are some evidences that vitamin D analogs can 
have positive regenerative effects after vascular injury, like previously been reported for 
healthy humans, diabetic mice models and conditional knockout of the vitamin 
D receptor mice [140]. In our work, paricalcitol had no effect in vdr expression, but we 
could detect an upregulation in the group treated with cinacalcet, in agreement with 
previous in vitro studies with rat parathyroid glands, demonstrating that class II 
calcimimetics induce a stimulatory affect in Vdr expression [141].  Additionally, gene 
expression analysis showed that both insa and insb were overexpressed in bone of 
diabetics treated with paricalcitol or cinacalcet. Other studies using analogs and 
calcimimetics have also shown to induce insulin expression and improve beta-cell 
proliferation and survival [142–145]. This can explain the fact that the regeneration 
process of the beta-cells occurred in a shorter period of time in the paricalcitol and 
cinacalcet treated groups by favoring insulin signaling and glucose metabolism. In the 
cinacalcet treated group we could observe a significant increase in insr suggesting an 
increased insulin signaling. In fact, VitD may have an important role in the treatment of 
diabetes as identified by Del Pino-Montes et al (2004) [146], who showed that 55% of 
diabetic rats treated with calcitriol recover from diabetes. Insulin expression have also 
been found to be increased in several tissues under diabetic conditions in both humans 
and mice [147], but in our study we could not observe such an increase in the non-
treated diabetic group, at least in the vertebral column. It has been demonstrated that 
insulin can be almost ubiquitously expressed in human [148], mice [147,149] and 
zebrafish [150] although at extremely low levels when compared to pancreatic insulin. 
Although not well understood, the function of extrapancreatic expression of insulin in 
some works was associated to local needs of glucose regulation specially under diabetic 
conditions [148,151] but in other reports this phenomenon was related to the 
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development of pathologic conditions [152]. Our results demonstrated that paricalcitol 
and cinacalcet can upregulate extrapancreatic expression of insulin including in bony 
tissues, like demonstrated for the vertebral column. In humans and animal models of 
diabetes, hyperglycemia leads to accelerated accumulation of advanced glycation end 
products (AGEs) [56], promoting an inflammatory response and increased apoptosis of 
cells expressing the receptor of AGEs such as osteoblasts [52,106]. In the non-treated 
diabetic group we could see impairment in osteoblastic activity, since osx, runx2 and oc 
expression was found to be downregulated compared to non-diabetics. In the diabetic 
groups treated with paricalcitol or cinacalcet, where an increase in mineralized area of 
the regenerated fin was observed, an upregulation of runx2 suggest an increase in the 
process of osteoblastic differentiation, contributing to the process of mineralization, in 
accordance with studies in humans, indicating that VitD effects on osteoblast 
differentiation are mostly stimulatory and associated with increased RUNX2 expression 
[153,154]. Additionally, in vitro studies with mesenchymal stem cells from human 
amniotic fluid have correlated calcimimetics with osteogenic differentiation and 
upregulation of bone markers including RUNX2 [155].  The principal objective of 
paricalcitol, cinacalcet and VitD in clinical treatment for SH, is to reduce parathyroid 
hormone secretion. We could observe a trend of reduced expression in pthr for all 
diabetic treated groups, suggesting reduced circulating parathyroid hormone, leading to 
a decrease in osteoclastic differentiation and bone resorption [156]. Nevertheless, VitD 
treatment alone could not explain our results, since the VitD treated group did not 
present such marked increase in mineralized area as the other two groups. This may be 
explained by the fact that VitD acts more slowly, at least when compared to paricalcitol 
[157]. Different pathways related to pth signaling, calcium metabolism or VitD induced 
osteoblastogenesis can be involved in the increase in bone mineralized and regenerated 
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areas observed in the caudal fin of zebrafish under diabetic conditions treated with 
paricalcitol and cinacalcet. Upregulation of insulin and increased osteoblastic 
differentiation induced by upregulation of runx2 and osx can explain our results. Both 
paricalcitol and cinacalcet were shown to have positive effects in promoting mineral 
deposition, counteracting bone loss related to diabetes, and may constitute an alternative 
therapy for prevention of bone related disorders observed in diabetes type I patients.  
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CHAPTER 4. CAN EXTRAPANCREATIC EXPRESSION 
OF INSULIN AND PARALOGS REGULATE GLUCOSE 
HOMEOSTASIS?  
4.1. Abstract  
To overcome type 1 Diabetes Mellitus all strategies should be taken seriously as 
this multifactorial disease has shown to be complex. In this work, we used data from 
human, mouse and zebrafish to try to understand (I) if insulin (INS) paralog, INS-IGF2 
can be a regulator of glucose in humans, and (II) if extrapancreatic expression of INS 
and INS-IGF2 can also play a role in the regulation of glucose levels. Phylogenetic 
analysis revealed two insulin genes occurring in mammals (INS, INS-IGF2) and in fish 
(insa and insb). Mice and all Murinae are an exception among mammals, since they lack 
INS-IGF2, having ins1 as paralogue of ins2, the ortholog of INS. Ins1, as well as Ins2 
can regulate glucose since both proteins are highly similar and with a redundant 
function, as confirmed by in vivo experiments that showed that both knockout Ins1 or 
Ins2 are normoglycemic. In zebrafish, the insb paralogue also suggest 
cofunctionalization with the ancestral gene, although identity between proteins is not as 
high as observed in mouse. In human, INS-IGF2 lacks motif 3 of the insulin signature, 
and part of the predicted protein structure does not present any known domain, which 
makes the prediction of a possible function for this gene inconclusive. Extrapancreatic 
expression of insulin has been observed in diabetic mice with contradictory effects, but 
available gene expression data in repository data banks also suggests that 
extrapancreatic expression of insulin occurs in human, mouse and zebrafish under basal 
condition. Weather the role of extrapancreatic insulin is to regulate glucose homeostasis 
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remains unknown. Further investigation should be made as this can represent a 
complementary strategy in diabetes treatment.     
4.2. Introduction 
Since the discovery of insulin in 1921 [158], patients with type 1 Diabetes Mellitus 
(T1DM) passed from a fatal prognostic to chronic patients, thanks to insulin 
replacement therapy. Although this treatment is the most widely peptide or protein 
based medicine used in the world [159], it was shown not to be totally efficient in 
treating all insulin-dependent diabetics, leading to morbidity later in life. The increasing 
worldwide prevalence of type 1 (T1DM) [4] and type 2 [2] Diabetes makes urgent the 
need for new strategies that can help stopping this uncontrolled pandemic. In humans 
the pre-pro-insulin is a protein with 110 amino acids (aa) encoded by the insulin gene. 
This peptide is composed by a signal peptide (1-24 aa), B chain (24-54 aa), C chain (57-
87 aa) and A chain (90-110 aa). After removal of the signal peptide (proinsulin) and the 
C chain, insulin reaches is final conformation with the A and B chains, and is ready to 
travel, from β-cells throughout the body as a hormone [159]. Insulin has been 
characterized as responsible for decreasing blood glucose concentration, increases cell 
permeability for monosaccharides, amino acids and fatty acids, accelerates glycolysis, 
pentose phosphate cycle and glycogen synthesis in liver, and together with IGF1 and 
IGF2 promotes embryonic growth [160]. Mouse has been the most widely animal model 
used for the study of diabetes [27,31,38,161], but recently, protocols for the induction of 
diabetes and transgenic lines in zebrafish have been developed [74,162]. The canonical 
gene of insulin in mouse is Ins2 and in zebrafish is insa while in human it is INS 
(Human insulin gene) and all sharing a high percentage of identity. In these three 
species we can find a paralog for insulin gene, being in mouse Ins1, in zebrafish insb 
and in human INS-IGF2. In human it has been identified a paralog of the insulin gene, 
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INS-IGF2 [163], which is a conjoined gene sharing INS gene in the 5' region and the 
IGF2 gene in the 3' region. INS-IGF2 is a parental imprinting gene that was first 
identified as being expressed both in the eye and pancreas [163] and a possible 
autoantigen like INS in T1DM [164]. In mouse, the two genes encoding for insulin, Ins1 
and Ins2, are thought to have duplicated because of an infection in the genetic material 
by a RNA virus originating Ins1 (retrogene).  Investigations done with mouse Ins1 or 
Ins2 knockouts (KO) revealed that Ins1 alone can regulate glucose homeostasis, 
although in some cases it cannot prevent type 1 diabetes mellitus (T1DM). Duvillie et 
al. [165] showed  that double Ins1 and Ins2 KO mice died prematurely, but mice lacking 
just one insulin gene were viable and fertile [165]. Leroux et al. [166], working with the 
same mutant lines observed, not only, that both Ins1 and Ins2 KO mice were 
normoglycemic, but that Ins2 KO mice had a dramatic increase in the expression of ins1 
accompanied with an increase in β-cell mass [166]. Babaya et al. [167], showed that 
Ins2 KO nonobese diabetic (NOD)  male mice, with just one ins1 allele, NODins1+/-,ins2-/-, 
developed diabetes at around 10 weeks of age, but males with both ins1 alleles 
NODins1+/+,ins2-/- and females from the two mutant lines only presented signs of diabetes 
later in life [167].    
In zebrafish the existence of two insulin genes (insa and insb) is likely due to the 
genome duplication event that occurred in the stem lineage of teleost fishes [150]. 
Papasani et al. [168], identified the second insulin gene in zebrafish and observed 
expression of insb both in pancreas and brain and suggested that it may regulate both 
autocrine/paracrine and endocrine systems via both insulin receptor a  (insra) and 
insulin receptor b insrb (14).  
In human extrapancreatic expression of insulin was first identified in brain [169] and 
then in thymus [170], has a way to the immune system recognize insulin, avoiding 
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autoimmunity and  β-cell destruction. Later Kojima et al showed the presence of cells 
that stained positive for insulin RNA in the liver, adipose tissue and  bone marrow in 
several diabetic mice models but not in nondiabetic mice [171,172]. However, this 
insulin expressing cells had no impact on hyperglycemia in diabetic mice. Later, 
Kojima et al. [173] demonstrated, that beside not having any impact in regulating 
glucose, this Proins/TNF-α-expressing cells had their origin in bone marrow and then 
migrated to several parts of the body, initiating diabetic neuropathy [152]. Cunha et al 
[174], in their experiments with diabetic mice treated with streptozotocin, observed 
beneficial effects in the secretion of insulin by the tear film of the eye and locally 
synthesized in the lachrymal gland [174]. Using in silico analyses we proposed to 
understand; 1) if INS-IGF2 can be a regulator of glucose homeostasis and 2) if 
extrapancreatic expression of both INS and INS-IGF2 can occur mimicking pancreatic 
INS action. 
4.3. Methods 
4.3.1. Phylogenetic tree construction 
To better understand the evolution of insulin genes we conducted a phylogenetic 
analysis of INS, INS-IGF2, Ins1, Ins2, insa and insb together from available sequences 
human, chimpanzee,  orangutan, gibbon, marmoset, otolemur, tree shrew, mouse lemur, 
squirrel, lesser jerboa, chinese hamster, rat, mouse, ferret, cat, panda, dolphin, cow, 
elephant, manatee, walrus, microbat, guine pig, hyrax, marmoset, coelacanth, frog, 
anole lizard, green sea turtle, duck, chicken, turkey, rock dove, collared flycatcher, 
zebra finch, ground tit, medium ground finch, white throated sparrow, tilapia, japonese 
pufferfish, green spotted puffer, zebrafish, medaka, platyfish, greater amberjack, 
stickleback and ciona intestinalis. Collection of protein sequences from insulin and 
paralogues was obtained in Ensembl Genome Browser (EGB) [175] and protein 
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database of National Center of Biotechnology Information (NCBI) [176]. We collected 
32 INS, 11 INS-IGF2, 2 ins1, 2 ins2, 7 insa and 5 insb protein sequences from the 
different species analyzed (Table 2). For multiple sequence alignment we used the 
algorithm Multiple Sequence Comparison by Log-Expectation (MUSCLE) [177]. Based 
on the sequence alignment results, the phylogenetic tree reconstruction was made using 
the Maximum-likelihood statistical method. Test of phylogeny was done using the 
bootstrap method and the number of replications was 1000. Phylogenetic and molecular 
evolutionary analyses were conducted using MEGA version 6 [178]. The insulin like 1 
precursor of 275 amino acids sequence of ciona intestinalis was used as an outgroup in 
the phylogenetic tree. 
4.3.2. Graphical representation of conserved motifs 
To determine percentage of identity between paralogs we aligned both proteins 
sequences for human, mouse and zebrafish species using algorithm MUSCLE and 
presenting it graphically using CLC Genomics Workbench v6.5 (CLC bio, Aaarhus, 
Denmark). Also, we applied INS, INS-IGF2, Ins1, Ins2 insa and insb  to InterProScan 
database [179] to identify insulin signatures and motifs present in protein sequences.  
4.3.3. Transcripts and gene expression  
To understand the pattern of expression of insulin genes in different tissues we 
gathered information available in data bases that provide transcriptome and microarray 
results from different experiments. Tissue gene expression pattern from insa 
(Dr.75811), insb (Dr.87912) and Ins2 (Mm.4946) were obtained from UniGene data 
base [180] and INS [181], INS-IGF2 [181] and Ins1 [182] from Expression Atlas [183]. 
Tissue distribution extrapancreatic expression of insulin were presented as  transcript 
per million. Graphic presentation was made using CIRCOS Circular Genome Data 
Visualization [184].  
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4.4. Results  
Insulin is an important regulator of life and not surprisingly, is conserved 
throughout all animalia kingdom including animals from subphylum tunicata like Ciona 
intestinalis. Our phylogenetic analyze (Figure 21) demonstrates that insulin paralogues 
INS-IGF2, ins1 and insb have different origins, INS-IGF2 is an exclusive gene of 
Mammals except for murinae (mouse and rat) that do not have INS-IGF2 gene, but 
instead have ins1 gene. On the other and chinese hamster, that belongs to the same order 
(rodentia) of mouse and rat possess INS-IGF2 gene.  
 
Table 2 – Insulin proteins, from the different species used for phylogenetic 
reconstruction 
Sl. No. Common name Scientific name 
Protein 
identification 
Length 
aa 
INS Human Homo sapiens NP_001172027.1 110 
Ins chimpanzee Pan troglodytes NP_001008996.1 110 
Ins Gorilla Gorilla Gorilla XP_004050475 110 
Ins Marmoset Callithrix jacchus XP_002755713 108 
Ins northern greater galago Otolemur XP_003798420 110 
Ins Tree Shree Tupaia chinensis XP_006141129 110 
Ins mouse lemur Microcebus murinus XP_012599453.1 110 
Ins Squirrel Ictidomys tridecemlineatus NP_001269184 110 
Ins lesser jerboa Jaculus jaculus XP_004654275.1 110 
Ins Chinese hamster Cricetulus griseus XP_007625431.1 110 
Ins2 Rat Rattus norvegicus AAA41439 110 
Ins2 Mouse Mus musculus NP_001172013.1 110 
Ins1 Rat Rattus norvegicus AAA41440.1 110  
Ins1 Mouse Mus musculus NP_032412.3 108 
Ins Ferret Mustela putorius furo XP_004759728.2 109 
Ins Cat Felis catus NP_001009272.1 110 
Ins Panda Ailuropoda melanoleuca XP_002920166.1 109 
Ins Dolphin Tursiops truncates XP_004317908 110 
Ins Cow Bos Taurus NP_001172055 105 
Ins Elephant Loxodonta Africana XP_003422420 105 
Ins Manatee Trichechus manatus latirostris XP_004389446.1 106 
Ins Coelacanth Latimeria chalumnae XP_006008147.1 107 
Ins Walrus Odobenus rosmarus XP_004403859.1 110 
Ins Guinea Pig Cavia porcellus XP_013006103.1 110 
Ins microbat Myotis lucifugus G1P146_MYOLU 105 
Ins coelacanth Latimeria chalumnae XP_006008147.1 107 
Ins frog xenopus laevis NP_001079350.1 106 
Ins Anole Lizard Anolis carolinensis G1KJA0_ANOCA 107 
Ins Chinese softshell turtle Pelodiscus sinensis K7G107_PELSI 108 
Ins Duck Anas platyrhynchos R0L6M4_ANAPL 107 
Ins Chicken Gallus gallus NP_990553.1 107 
Ins turkey Meleagris gallopavo XP_003206326.1 107 
Ins Rock dove Columba livia XP_005499300.1 107 
Ins collared flycatcher Ficedula albicollis XP_005046861.1 107 
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Ins Zebra finch Taeniopygia guttata H0ZG98_TAEGU 107 
Ins Ground tit Pseudopodoces humilis XP_005522396.1 107 
Ins Medium ground finch Geospiza fortis XP_005427262.1 107 
Ins White-throated sparrow Zonotrichia albicollis XP_005486624.1 107 
Insa Tilapia Oreochromis niloticus I3IUZ1_ORENI 123 
Insa Japanese pufferfish Takifugu rubripes XP_003978300.1 120 
Insa 
Spotted green 
pufferfish 
Tetraodon nigroviridis Q4T1L5_TETNG 89 
Insa Medaka Oryzias latipes H2MW49_ORYLA 115 
Insa Southern platyfish Xiphophorus maculatus M4AFY5_XIPMA 117 
Insa greater amberjack Seriola dumerili BAE96120.1 116 
Insa stickleback Gasterosteus aculeatus ENSGACG00000001771 117 
Insb Tilapia Oreochromis niloticus I3KM26_ORENI 111 
Insb Japanese pufferfish Takifugu rubripes H2RZ45_TAKRU 110 
Insb Zebrafish Danio rerio NP_001034153.1 107 
Insb Medaka Oryzias latipes H2MXM6_ORYLA 113 
INS-IGF2 Gibbon hylobates lar G1RSR9 222 
INS-IGF2 Rock hyrax Procavia capensis ENSPCAT00000013013 206 
INS-IGF2 Chinese hamster Cricetulus griseus EGW08477.1 248 
INS-IGF2 Human Homo sapiens ABD93453.1 200 
INS-IGF2 Orangutan Pongo pygmaeus H2NCF9_PONAB 199 
INS-IGF2 Marmoset callithrix jacchus F7FC22_CALJA 194 
INS-IGF2 Elephant Loxodonta africana G3TLG9_LOXAF 202 
INS-IGF2 Manatee Trichechus manatus XP_004389487.1 339 
INS-IGF2 Ferret Mustela putorius M3Y2P9_MUSPF 192 
INS-IGF2 Walrus Odobenus rosmarus XP_004403860.1 199 
INS-IGF2 Panda Ailuropoda melanoleuca D2HDS9_AILME 212 
insulin-like 2 Ciona intestinalis Ciona intestinalis NP_001123345.1 130 
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Figure 22. Phylogenetic tree of insulin, INS INS-IGF2, Ins2, Ins1, insa and insb proteins  
Sequences were obtained in Ensembl Genome Browser [175], aligned using MUSCLE 
[177] and phylogenetic and molecular evolutionary analyses were conducted using 
MEGA version 6 [193]. For outgroup it was used insulin like 1 precursor protein 
sequence from Ciona intestinalis. Green circle INS, INS-IGF2 duplication, Blue circle 
Ins1, Ins2 duplication, red circle insa, insb duplication. Numbers at the branches 
represented the bootstrap support values.  
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The Insb paralogue seems to be exclusive of osteichthyes, and probably all 
species from this superclass have a second insulin gene, as we have identified possible 
regions for insb in the genome of stickleback and platyfish (data not shown). Transcript 
analyses (Figure 22) demonstrate that the regulatory elements of INS in human and ins2 
in mouse are well conserved, since for each human transcript there is a similar mouse 
transcript (NP_000198.1 similar to NM_001185083.1, NP_001172026.1 similar to 
NM_008387.4, NP_001172027.1 similar to NM_001185084.1) except for ins2-006. 
Other transcripts are annotated in  EGB [175], for ins2 (ins2-003, ins2-004 and ins2-
008), that predict protein structures smaller than the canonical sequence and this may 
need of further investigation to confirm it´s evidence. In zebrafish insa, presents only 
one known transcript, constituted of 3 exons like its human and mouse orthologues. Insb 
presents 3 different transcripts one with also 3 exons (NP_001034153.1) and two 
transcripts with 5 exons and a different coding DNA sequence, with the predicted 
protein being of more 49 aminoacids.   
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human INS Chr 11 
human INS-IGF2 Chr 11 
zebrafish insb Chr 14 
mouse Ins1 Chr 19 
mouse Ins2 Chr 7 
zebrafish insa Chr 5 
Figure 23. Transcripts for INS and INS-IGF2 in Human, ins2 and ins1 in mouse, insa and insb in zebrafish.  
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Two transcripts have been identified for INS-IGF2 were the two first exons 
share the same open reading frame (ORF) and coding DNA sequence (CDS) of INS 
transcripts, two other exons with CDS that encode for some unknown protein domain 
(confirmed by InterProScan [179], data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78,95% 
zebrafish 
94,44% 100% 
100% 6,67% 
human 
mouse 
 
Motif 1 and 2  Motif 3 
conservation 
conservation 
40% conservation 
Figure 24. Mouse and zebrafish insulin paralogs are highly similar, but Human paralog 
INS-IGF2 don´t have the third motif of insulin protein 
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Only one copy of ins1 is identified and this transcript presents a large size and 
structure similarities with of ins2, but without the second intron. Moreover, insa gene 
has only one known transcript and its structure is highly conserved compared with 
homologs INS and ins2, being identicaly constituted by 3 exons and with a similar size 
and structure. Insulin paralog insb of zebrafish presents 3 different transcripts, although 
the one annotated in NCBI (NP_001034153.1) seems to be a shorter versions of the 
insb-001 and insb-002 present in EGB [175] and recently in our lab we have confirmed 
the existence of this two predicted transcripts by PCR amplification and sequencing. 
After, we aligned protein sequences (Figure 23) of human, mouse and zebrafish 
paralogs to understand the degree of conservation of the new insulin genes with 
ancestral genes. In human motif 1 and 2 of INS and INS-IGF2 are 100% identical as 
both proteins are translated from the same CDS, but INS-IGF2 lacks motif 3 signature 
from INS confirmed by InterProScan motif prediction [179]. On the other hand, mice 
paralogs have all three motif regions very well conserved, with an homology of motif 1 
and 2 of 94,44% and motif 3 100%.  Although not as conserved as mouse paralogs, in 
zebrafish, insb, seems to be reasonably conserved, as InterProScan [179] predicts the 
existence of the 3 insulin motifs, being the identity of insa and insb of 78,95% in motif 
1 and 2 and of 40% in motif 3. In the past few years there has been a growing body of 
evidences showing that insulin can be expressed in several tissues beside pancreas. Here 
we show (Figure 24) data from transcriptome and microarray obtained in the repository 
data bases UniGene [180] and Expression atlas [183] demonstrating that in human, 
mouse and zebrafish there are indications of insulin expression in different tissues. 
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Figure 25. Gene expression data in different tissues, available in data banks, suggests that in all 3 species 
insulin is expressed outside the pancreas. In Human INS is expressed artery (art), kidney (kid), esophagus 
(eso), adipose tissue (a_t), adrenal gland (a_g), appendix (app), bladder (bla), muscle (mus), colon (col), 
duodenum (duo), heart (hea), liver (liv), prostate (pro), salivary gland (s_g), skin (ski), intestine (int), 
spleen (spl), stomach (sto), pituitary gland (p_g), reproductive system (r_s). INS-IGF2 was found in liver 
(liv), brain (bra), dura mater (d_m) and reproductive system (r_s). In mouse ins1 expression was found in 
colon (col), stomach (sto) and intestine (int), but no expression of ins2 was detected [182]. In zebrafish 
obtained data suggests that insa expression is restricted to pancreas while insb is expressed in brain, 
reproductive system, muscle, liver and kidney. 
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 Human sequence analysis [181] showed that INS can be expressed in artery, 
kidney, esophagus adipose tissue, adrenal gland, appendix, bladder, muscle, colon, 
duodenum, heart, liver, prostate, salivary gland, skin, intestine, spleen, stomach, 
pituitary gland, reproductive system. Also extrapancreatic expression of INS-IGF2 
could be detected in liver, brain, dura mater and reproductive system [181]. In our 
review of mouse sequences we could found evidences of expression in colon, stomach 
and intestine for the ins1 gene but no extrapancreatic expression of ins2 [182]. Similar 
results could be found in zebrafish as insa expression seems to be restricted to pancreas 
while insb was found in brain, reproductive system, muscle, liver and kidney. 
4.5. Discussion 
Strategies to overcome T1DM have been diverse, from vaccines [185], stem 
cells and pancreas transplantation [186,187], drug [188] and antibody therapy [189], 
with promising results in finding a possible cure. Other possible solutions, like 
extrapancreatic expression of insulin, have taken a marginal place although it could 
have some therapeutic potential in specific cases. The first question that we tried to 
answer was if INS-IGF2 could mimic the role of its ancestral. INS-IGF2 does not have 
all the conserved motifs of INS and although this may suggest other functions for this 
gene, data bases like STRING [190] recognize a protein interaction with INSR. INS, 
INS-IGF2 duplication event in mammals preceded the ins1 and ins2 duplication. It is 
possible that the conservation of ins1 led to the elimination of INS-IGF2 in Murinae, 
probably because it presents a protein structure extremely similar to ins2 and can, with 
accuracy, mimic ancestral gene function better than INS-IGF2. The cofunctionalization 
of ins1 and ins2 could be demonstrated in KO mice lacking ins2. These mutants did not 
present signs of diabetes and could stay normoglycemic by overexpressing ins1and 
increasing β-cell mass [166]. Finally, ins1 replaced INS-IGF2 in Murinae genomes, 
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because it was more efficient in performing the role ins2. Nevertheless, part of the INS-
IGF2 protein sequence that is different from the INS, lacks any known domain that 
could also suggest neofunctiolization for this gene, although this has not yet been 
described. Additionally, a recent published work [191] observed that after trying to 
detect INS-IGF2 by both Western blotting and immunohistochemistry in a human beta 
cell line they only detected cross reaction to native proinsulin, concluding that there is 
no evidence of a mature protein from INS-IGF2. Further investigations have to be 
performed to understand if INS-IGF2 can have some biological function or if it just a 
pseudogene. Evidences of extrapancreatic expression of insulin are becoming the rule 
rather than the exception. Large scale genome-wide association studies like The 
Genotype-Tissue Expression (GTEx) project [181], are enabling a global view of the 
gene expression in Human tissues. In this work the researchers could detect INS 
expression in twenty different tissues and INS-IGF2 in four. Transcriptome analyses in 
mouse and zebrafish suggest that extrapancreatic expression of insulin  is achieved by 
ins1 and insb[180,182]. Although we look at this data with enthusiasm, we have the 
perfect conscience that the levels of expression, in some tissues, are very low and that 
proofs of protein secretion are needed. Evidences of extrapancreatic and extrathymic 
translation of insulin have been demonstrated in mice [173]. Although in this case these 
insulin producing cells had origin in bone marrow and migrated to different parts of the 
body, and were associated with the onset of diabetic neuropathy. Other studies could see 
advantages in the secretion of insulin by tear film cells, under diabetic conditions  [174]. 
Recently in our lab, we could detect both insa and insb expression in kidney, muscle 
and bone in WT zebrafish under non diabetic conditions. Also, in a diabetic zebrafish 
model of diabetes, we could detect increased expression of both genes in bone after 
treating them with a vitamin D analog and a calcimimetic [192], demonstrating that not 
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only pancreatic INS expression is sensitive to some types of treatments [142,144], but 
also that this drugs can have the same effect in other cell types including bone. In this 
work we have gathered evidence that in mice, and probably in zebrafish, insulin 
paralogues can regulate glucose homeostasis, but in Human the answer is not clear.  
Extrapancreatic expression of insulin occurs in the three studied species and, at least in 
zebrafish, it is sensitive to drug therapy. If confirmed, the therapeutic potential of this 
event would be of considerable relevance for the treatment of diabetes, as this could 
represent a simple, reliable and safe way for self-production of insulin.  
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CHAPTER 5. GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES  
Bone pathologies related to DM are rapidly becoming one of the principal 
causes associated to morbidity and tend to increase as both types of DM keep on 
growing worldwide [2]. During the onset and progression, T1DM can affect several 
different organs and tissues including bone. The fact that T1DM can alter metabolism, 
induce inflammation, increase apoptosis and growth retardation, as made a challenging 
task to determine the true causes of bone changes.  
In chapter 1we believe to have contributed with novel evidences on how T1DM 
affects bone. Our most important finding is that a possible leptin deficiency can be an 
important cause that modulates bone changes in diabetes. We believe that previously 
authors have skipped this phenotype since the studies using diabetic mice models were 
not performed beyond 3 months. In fact, previous studies with hipoleptinemic mice 
revealed that this microarchitecture changes could only be detected starting at 4 months. 
But probably reduced leptin signaling in bone cells is not the only explanation for our 
results since the lack of insulin signaling in bone cells also reduces bone resorption and 
formation, leading us to propose that in our study hipoinsulinemia as contributed to the 
reduced bone formation phenotype. Additionally, our results suggest that there are 
increased signs of inflammation in the bone environment, as detected by an increase of 
enzymes involved in cartilage degradation that could explain the growth retardation of 
our diabetic mice. It was observed that leptin deficient mice also presented growth 
retardation and that chondrocytes express the leptin receptor and once again leptin 
deficiency could be the explanation for impaired growth. To the best of our knowledge, 
treatment of diabetic mice with leptin was tested with no effects on bone volume [38], 
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besides this, future works in this field should reconsider leptin treatment as a way to 
revert this bone phenotype. 
In chapter 3 we report an increase in fin regeneration and mineralization in a 
zebrafish model of diabetes after treating this transgenic fish with paricalcitol and 
cinacalcet. We could validate this model as suitable for the study of bone pathologies 
related to diabetes and a response to vitamin D metabolism was achieved with benefits 
for preventing bone growth retardation. Indeed, non-treated diabetic group had impaired 
fin regeneration and mineralization with increased blood glucose levels. There are other 
protocols for the induction of diabetes in zebrafish, particularly the STZ method, but 
with more side effects than the one used in our studies.  
Beside paricalcitol and cinacalcet, we also tested VitD3 but the results only 
showed a trend of increase of bone formation. The treatments tested are currently used 
as therapeutic solutions to treat SH, and in these patients the results suggest that 
treatment with VitD can have the same positive results as paricalcitol and cinacalcet, but 
with more prolonged exposure periods. Also, if in our study the exposure and 
regeneration period had been longer, the VitD group probably could have had a more 
pronounced effect on fin mineralization and regeneration.   
To better interpret our results we performed a gene expression analysis by qRT-
PCR to a group of genes of interest and we could detect a trend of decrease in all three 
treated groups for pthr that could be related to a decrease in circulating pth, inhibiting 
bone resorption. But this result alone could not explain the observed increased 
regenerated and mineralized areas in the paricalcitol and cinacalcet groups, because the 
VitD group did not show the same increase. Other explanation could be the increased 
expression of runx2 found in paricalcitol and cinacalcet groups that could have triggered 
an increase in osteoblast differentiation.  
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Finally we could detect insa and insb expression in RNA from muscle, kidney 
and bone supporting the conclusions in the previous chapter. But more interestingly, 
was the fact that both insa and insb were upregulated in the paricalcitol and cinacalcet 
treated groups. Despite these results we feel more comfortable to say that both 
paricalcitol and cinacalcet may have increased the expression of insulin in the pancreas, 
as it was previously described that activation of VitD receptor and calcium sensing 
receptor induce insulin expression in the pancreas.  
Future studies should focus in understanding if both drugs actually favor 
osteoblastic differentiation and if upregulation of insulin could actually explain these 
results.    
In chapter 4 we focused on two possibilities: i. Does the INS-IGF2 gene have the 
capacity to mimic the action of its paralogue INS and; ii. Does extrapancreatic INS 
expression occurs and if it has any function in regulating glucose.  
Our in silico analysis showed that INS-IGF2 do not have all the motifs that 
characterize INS transcripts. Murinae have two redundant insulin genes, that we believe 
that the  rise of ins1 favored the loss of Ins-Igf2 in this subfamily suggesting that both 
genes could have the same function, but hardly INS-IGF2 in humans can have a 
redundant function with INS. The zebrafish genome also contains two different insulin 
genes with all the motifs. This suggests co-functionalization, like the observed in mice.  
Extrapancreatic expression of insulin is a proven fact and in our work we have 
gathered data that supports this statement. In mouse and zebrafish this expression is 
mainly made by paralogues while in human is made by INS. Although this could have 
therapeutic potential, little is known on how this process is regulated. Some researchers 
have linked extrapancreatic expression of insulin to diabetes with consequences in 
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development of other diseases, but others have observed beneficial effects in local 
secretion of insulin by different organs.         
Future works in this field should first understand if extrapancreatic insulin is 
translated and secreted, and if this can be potentiated, favoring overall body metabolism 
in diabetes. 
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APPENDIX I 
Table 1. Primers for qRT-PCR used in chapter 2  
mouse 
Oc Forward AAGCAGGAGGGCAATAAGGTAGTGAACA 
Oc Reverse GAGTTTGGCTTTAGGGCAGCACAGGTC 
Runx2 Forward AGGGAGAGGACAACAGAAGAGAA 
Runx2 Reverse TCAAAGTAAAGTGGGACTGCCTAC 
Adamst5 Forward TCAGCCACCATCACAGAA 
Adamst5 Reverse CCAGGGCACACCGAGTA 
Hrrpt1 Forward GGTGGATATGCCCTTGACTATAATGA 
Hrrpt1 Reverse CAACATCAACAGGACTCCTCCTATT 
ColII Forward CCAACACCGCTAACG 
ColII Reverse GGTCTTGCCCCACTTAC 
Igf1 Forward AAAGTGGTCCTGGCGTGGGTAGATT 
Igf1 Reverse TCTACAACATCCATGCATTTTCGGC 
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APPENDIX 2 
Table1. Primers used for qRT-PCR in chapter 3  
zebrafish  
ef1a Forward AGC CCC TCC TGG CTT TCA CCC 
ef1a Reverse TGG GAC GAA GGC AAC ACT GGC 
18s Forward ACCACCCACAGAATCGAGAAA 
18s Reverse GCCTGCGGCTTAATTTGACT 
Runx2 Forward GCACGGAGAGGGACTGACGG 
Runx2 Reverse AGGGCCACCACCTTAAACGC 
Oc Forward CCAACTCCGCATCAGACTCCGCATCA 
Oc Reverse AGCAACACTCCGCTTCAGCAGCACAT 
Osx Forward GTTTCCCAGGACCCTTCGCT 
Osx Reverse GCAATCGCAAGAAGACCTCC 
pth1ra Forward GTTTCGTCTATGGTCTGGTCG 
pth1ra Reverse GATTGCTCGCTCACATTTTC 
Vdr Forward GTCCAACCAGTCCTTCAGTCT 
Vdr Reverse AGTGTGACCCGCCTTAGTG 
Insb Forward CTCTGCTCACTCAGGAAAAGG 
Insb Reverse GGATGGAGAAGACTGCGAT 
Insa Forward CATTCCTCGCCTCTGCTTC 
Insa Reverse TGCCTGGGTTAGTGCTTACA 
Insra Forward TCTACAGCGAGGAAAACAAGC 
Insra Reverse AGAGATAAGATGCGTCCGTTTT 
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APPENDIX 3 
 
List of protein sequences used for phylogenetic tree reconstruction in 
chapter 4:  
#Human 
>homo sapiens sapiens_INS 
MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTP
KTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLE
NYCN 
>homo sapiens sapiens_INS-IGF2 
MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTP
KTRREAEDLQASALSLSSSTSTWPEGLDATARAPPALVVTANIGQAGGSSSRQF
RQRALGTSDSPVLFIHCPGAAGTAQGLEYRGRRVTTELVWEEVDSSPQPQGSES
LPAQPPAQPAPQPEPQQAREPSPEVSCCGLWPRRPQRSQN 
#chimpanzee 
> Pan troglodytes 
MALWMRLLPLLVLLALWGPDPASAFVNQHLCGSHLVEALYLVCGERGFFYTP
KTRREAEDLQVGQVELGG 
GPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN 
>gorilla gorilla gorilla Ins 
MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTP
KTRREAED 
LQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN 
>gorilla gorilla gorilla INS-IGF2 
PSRTGCIRRGHQAGHCPSAMALWMRLLPLLALLALWGPDPAPAFVNQHLCGS
HLVEALYLVCGERGFFYTPKTRREAEDPQASALSPSSSTSTWPEGLDATARAPP
ALVATANFGQVGGSSSRQFRQRALGTSDSPVLFIHCPGAAGTARGLEYRGRRV
TTELVWEEVDSSPQPQGSESLPAQPPAQPAPQPEPQQARAAGEPSPEVSCCGLW
PRRPQRSQN 
#Marmoset 
>Callithrix jacchus 
MAPWMPLLPLLALLALWGPEPAPAFVNQHLCGPHLVEALYLVCGERGFFYAP
KTRREAEDLQVGQVELGGGSITGSLPALEGPLQKRGVVDQCCTSICSLYQLQNY
CN 
#Marmoset_ 
>Callithrix jacchus_INS-IGF2 
MAPWMPLLPLLALLALWGPEPAPAFVNQHLCGPHLVEALYLVCGERGFFYAP
KTRREAEDLQASALSPSSSSTSTRLEGLNATPALVATAHIGQASGAPSWQLRQT
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ALGTSDPVLFTHCPGAVGTQQRLESGGEGATAPLQEVDSSPQPRGSEPLPAHPA
QPAPQPEPEQARPESSPEVSCCGLWPRRAQHSQN 
#Ferret 
>Mustela putorius furo 
MALWMRILPLLALLALWAPAPTAAFVNQHLCGSHLVEALYLVCGERGFFYTP
KARREAEDLQARDSELGGAPGAGGLALGLEGALQKRGIVEQCCTSICSLYQLE
NYCN 
>Mustela putorius furo_INS-IGF2 
MPLPASAVSIPRSPSPAMALWMRILPLLALLALWAPAPTAAFVNQHLCGSHLVE
ALYLVCGERGFFYTPKARREAEDLQASASSPASTSSTRLEGLGTTARAPPALAA
TANIGPTSGSPAGQLQQRGLGSGDSPVLFIHRPGTSGTTQRLEYRGRRVTAELPE
EEVAPQPQGPTSHPAEPPAQPAPQPEPKAARATREPSPELRCCGLWPRQSGRAQ
N 
#Elephant 
> Loxodonta africana Ins 
MALWTRLLPLLALLAVGAPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRREVEDTQVGEVELGTGLQPFPAEAPKQKRGIVEQCCTGVCSLYQLENYCN 
> Loxodonta africana INS-IGF2 
MALWTRLLPLLALLAVGAPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRREVEDTQASSTSTSSSPSTRLEGLGTTARAPPALAATANIGPTSGSSAGQFQE
RALGTSDSPVLIIHRPGAAGTAQRLEYRGRRVTADLVEEEVGTRPQHQGPPAGP
AHSAYPLAQPALQPARASRDPSPEVSCCGLWPQRSQRSQN 
#Orangutan 
>Pongo borneo 
MALWMRLLPLLALLALWGPDPAQAFVNQHLCGSHLVEALYLVCGERGFFYTP
KTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLE
NYCN 
>Pongo borneo_INS-IGF2 
MALGMRLLPLLALLALWGPDPAQAFVIFRLCGSHLVEALYLLFGERGFFYTPKT
RREAESALSPSSSTSTWPEGLDATARAPPALVATANIGQAGRSSSRQFRQRALG
TSDSPVLFIHCPGAAGTAQGLGYRGRRVTAELVWEEVDSSPQPQGSESLPAQPP
AQPAPEPEPQQARVAREPSPEVSCCGLWPRRPQRSQN 
#Manatee 
>Trichechus 
MALWTRLLPLLALLAVGAPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRRELEDPQVGKVEPGAGGRQPFPAEVPREKRGIVEQCCTGVCSLYQLENYCN 
>Trichechus_INS-IGF2 
MALWTRLLPLLALLAVGAPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRRELEDPQASSTSTSSSPSTRLEDLGTTARTPPALAATANIGPTSGSSTGQFQQR
DLGTSNSPVLIIHRPGAAGTAQRLEYRGRRVTAELVQEELGTRPQHQGPPAHPA
CLAHPPAQPAPQPEPQQARASRDPSPEVSCCGLWPQRSQRSQN 
#Walrus 
>Odobenus rosmarus 
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MALWTRLLPLLALLAVGAPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRRELEDPQVGKVEPGAGGRQPFPAEVPREKRGIVEQCCTGVCSLYQLENYCN 
>Odobenus rosmarus_INS-IGF2 
MALWTHLLPLLALLALWAPAPSRAFVNQHLCGSHLVEALYLVCGERGFFYTPK
ARREVEDPQASASSPSSSSTSTRLEGLGTAARAPPTLAATANIGPTSGSSAGQLQ
QRGLGTSDSPVLFIHRPGTSGTTQRLEYRGRRVTAELLEEEVDPKPQGPASHPAE
TPAQATPQPEPQAAREPSREVSCCGLWPRWSPRAQN 
#Panda 
>Ailuropoda melanoleuca 
MALWTRLLPLLALLAVWAPVPARTFVNQHLCGSHLVEALYLVCGERGFFYTP
KARREVEDLPAGDAELDRVPGADPQPRALAGALQRRGIVEQCCTSICSLYQLEN
YCN 
>Ailuropoda melanoleuca_INS-IGF2 
MALWTRLLPLLALLAVWAPVPARTFVNQHLCGSHLVEALYLVCGERGFFYTP
KARREVEDLPASASSPSSSSTSTRLEGLGTTARAPPTLAATANTGPTSGSSARQF
RQRDLGTSDSPVLFIHRPGTSGTTQRLEYRGRRVTGELLEEEVDPKPQSPASHPA
EPPAQVAHQPEPQLEPQTQSEPKPARTTREPSPEVSCCGLWPRRSPHAQN 
>Hyrax 
#Procavia_INS-IGF2 
MALWTRLLPLLALLAVGPPPPARAFVNQHLCGSHLVEALYLVCGERGFFYTPK
ARREVEDPQAPPPSTSPSASTRLQGLDLTARAPPALSETDNTSPTGGPPAGQFQE
TAFGTSDSPVLTIHHPGAAGTPQQLEFRGQSVTTGLVEEEEASTRPQHQSPPPLP
ALPPAQPAPQPKLQQVRFSRDPSPEVRCCGLWPWRRSWHLQN 
#Chinese_hamster 
>Cricetulus griseus 
MALWMRLLPLLALLALWEPNPAQAFVNQHLCGSHLVEALYLVCGERGFFYTP
KSRRGVEDPQVTQLELGGGPGAGDLQTLALEVAQQKRGIVDQCCTSICSLYQL
ENYCN 
>Cricetulus griseus_INS-IGF2 
MALWMRLLPLLALLALWEPNPAQAFVNQHLCGSHLVEALYLVCGERGFFYTP
KSRRGVEDPQASASSPSTSSTSTRLERLGTTARAPPALEEVADPGPASRSSPKQF
RKRIFGTSEPPVLFIHRPGASGTTKRLEYRGRVVTTELQVIVQEEDPEPQSRGPAS
PGDEPLAQPPKPLPRPEPQRPEPSPEARCCGLWPRRSQRSQN 
#Rat 
>Rattus norvegicus_INS1 
MALWMRFLPLLALLVLWEPKPAQAFVKQHLCGPHLVEALYLVCGERGFFYTP
KSRREVEDPQVPQLELGGGPEAGDLQTLALEVARQKRGIVDQCCTSICSLYQLE
NYCN 
>Rattus norvegicus_INS2 
MALWIRFLPLLALLILWEPRPAQAFVKQHLCGSHLVEALYLVCGERGFFYTPMS
RREVEDPQVAQLELGGGPGAGDLQTLALEVARQKRGIVDQCCTSICSLYQLEN
YCN 
#mouse 
#mus musculus_INS1 
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MALLVHFLPLLALLALWEPKPTQAFVKQHLCGPHLVEALYLVCGERGFFYTPK
SRREVEDPQVEQLELGGSPGDLQTLALEVARQKRGIVDQCCTSICSLYQLENYC
N 
>mus musculus_INS2 
MALWMRFLPLLALLFLWESHPTQAFVKQHLCGSHLVEALYLVCGERGFFYTP
MSRREVEDPQVAQLELGGGPGAGDLQTLALEVAQQKRGIVDQCCTSICSLYQL
ENYCN 
#Squirrel 
>Callosciurini 
MALWTRLLPLLALLALLGPDPAQAFVNQHLCGSHLVEALYLVCGERGFFYTPK
SRREVEEQQGGQVELGGGPGAGLPQPLALEMALQKRGIVEQCCTSICSLYQLEN
YCN 
#Tree_shrew 
>Anathana ellioti 
MALWTCFLPLLTLLALWGPEPAPAFVNQHLCGSHLVEALYLVCGERGFFYTPK
TRREVEDSQGQVELRGPAGSLQPLALEVPPQKRGIVEQCCTSICSLYQLENYCN 
#Dolphin 
>Tursiops truncatus 
MVLWLRLGPLLALLALWAPAPARAFVNQHLCGSHLVEALYLVCGERGFFYTP
KARREVEGPQVGAVELGGGPGAGGLQPPALEGPPQKRGIVEQCCTSICSLYQLE
NYCN 
#Otolemur 
>Otolemur agyisymbanus 
MAVWMRLLPLLALLALWGPEPAPAFVNQHLCGSHLVEALYLVCGERGFFYTP
KARRDTEDPQVGQVGLGGSPITGDLQSLALDVPPQKRGIVEQCCTSICSLYQLE
NYCN 
#Lesser_E_jerboa 
>Pygeretmus platyurus 
MTLWTRLLPLLALLALWGADPAQAFVNQHLCGSHLVEALYLVCGERGFFYTP
KSRREVEDPQAGQLELGGGPGAGGPQSLALELAPQKRGIVDQCCTSICSLYQLE
NYCN 
#Mouse_lemur 
>Microcebus murinus 
MALWTRLLPLLALLALWGPEPAPAFVNQHLCGSHLVEALYLVCGERGFFYTPK
SRREVEDAQAGQVGPDGGLGAGGLQALALEGAPQKRGIVEQCCTSICSLYQLE
NYCN 
#Microbat 
>Corynorhinus townsendii 
MALWTRLLPLLALLALWAPAPAQAFNHEHLCGEDLVDIMTIICGDQGFKNPKA
ARELPDPQEGEVDMGAGGPKALTVEELLQNTDIVEVCCTNICSFYDMETYCN 
#Cow 
>Bos taurus 
MALWTRLAPLLALLALWAPAPARAFVNQHLCGSHLVEALYLVCGERGFFYTP
KARREVEGPQVGALELAGGPGAGGLEGPPQKRGIVEQCCASVCSLYQLENYCN 
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#Cat 
>Felis catus 
MAPWTRLLPLLALLSLWIPAPTRAFVNQHLCGSHLVEALYLVCGERGFFYTPK
ARREAEDLQGKDAELGEAPGAGGLQPSALEAPLQKRGIVEQCCASVCSLYQLE
HYCN 
#Guine_pig 
>Cavia porcellus 
MALWMHLLTVLALLALWGPNTGQAFVSRHLCGSNLVETLYSVCQDDGFFYIP
KDRRELEDPQVEQTELGMGLGAGGLQPLALEMALQKRGIVDQCCTGTCTRHQ
LQSYCN 
#Chicken 
>Gallus gallus domesticus 
MALWIRSLPLLALLVFSGPGTSYAAANQHLCGSHLVEALYLVCGERGFFYSPK
ARRDVEQPLVSSPLRGEAGVLPFQQEEYEKVKRGIVEQCCHNTCSLYQLENYC
N 
#Ficedula albicollis 
>Collared_Flycatcher 
MALWLRSLPLLALLALSSPGSSQAAVSQHLCGSHLVEALYLVCGERGFFYQPK
ARRDVEQPLAYQQRCLSGPLHGELGELPFQQEEFEKVKRGIVEQCCHNTCSLY
QLENYCN 
#Rock_Dove 
>Columba livia 
MALWIRSLPLMALLALSGPGTSHAAANQHLCGSHLVEALYLVCGDRGFFYSPK
ARRDIEQPLVSGPLHGEIGELPFQQEEFEKVKRGIVEQCCHNTCSLYQLENYCN 
#Turkey 
>Meleagris gallopavo 
MSLWIRSLPLLALLVFSGPGTSYAAANQHLCGSHLVEALYLVCGERGFFYSPKA
RRDVEQPLVSSPLRGEAGVLPFQQEEYEKVKRGIVEQCCHNTCSLYQLENYCN 
#Duck 
>Bucephala clangula 
MALWIRSLPLLALLALSGPGISHAAANQHLCGSHLVEALYLVCGERGFFYSPKT
RRDVEQPLVNGPLHGEVGELPFQHEEYQKVKRGIVEQCCENPCSLYQLENYCN 
#Zebra_finch 
>Taeniopygia guttata 
MALWIRSLPLLALLAVSGPGSSHGAVNQHLCGSHLVEALYLVCGERGFFYQPK
ARRDVEQPLVSGPLHGELGELPFQQEEFETVKRGIVEQCCHNTCSLYQLENYCN 
#Budgerigar 
>Melopsittacus undulatus 
MALWILSLPLLALLALSGPGTSHAAATQHLCGSHLVEALYLVCGERGFFYSPKA
RRDVEQPLVSGPLHGEVGELPFRPEEFQKVKRGIVEQCCHNTCSLYQLENYCN 
#Ground_Tit 
>Pseudopodoces humilis 
MALWIQSLPLLALLAFSGPGSSHAAVNQHLCGSHLVEALYLVCGERGFFYQPK
ARRDVEQPLVSGPLHGELGELPFQQEEFEKVKRGIVEQCCHNTCSLYQLENYCN 
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#Medium_Ground_Finch 
>Geospiza fortis 
MALWIRSLPLLALLALSGPGSSHAAVNQHLCGSHLVEALYLVCGERGFFYQPK
ARRDAEQPLVSGPLHGELGELPFQQEEFEKVKRGIVEQCCHNTCSLYQLENYCN 
#White_Throated_Sparrow 
>Zonotrichia albicollis 
MALWIRSLPLLALLALSGPGSSHAAVNQHLCGSHLVEALYLVCGERGFFYQPK
ARRDAEQPLMSGPLHGELGELPFQQEEFEKVKRGIVEQCCHNTCSLYQLENYC
N 
#Anole_lizard 
>Anolis carolinensis 
MTLWISSLPLLVLIAVSAPTISYALPNQHLCGSHLVEALYLVCGDRGFYYSPKTR
RNIEQPLASGSLQNEVETLPFQPQDFQKVKRGIVQQCCENTCSLYELENYCN 
# Chinese softshell turtle 
> Pelodiscus sinensis  
MALWIRSLPLLALLALSGPPISHAAANQHLCGSHLVEALYLVCGERGFFYSPKA
RRDLEQPLVRQRGAPQNEVELPFQQQEFQQAKRGIVEQCCHNTCSLYQLENYC
N#Frog 
>Xenopus laevis 
MALWMQCLPLVLVLLFSTPNTEALANQHLCGSHLVEALYLVCGDRGFFYYPKI
KRDIEQAMVNGPQDNELDGMQLQPQEYQKMKRGIVEQCCHSTCSLFQLESYC
N 
>danio rerio_Insa 
MAVWLQAGALLVLLVVSSVSTNPGTPQHLCGSHLVDALYLVCGPTGFFYNPK
RDVEPLLGFLPPKSAQETEVADFAFKDHAELIRKRGIVEQCCHKPCSIFELQNYC
N 
>danio rerio_Insb 
MGTFVFPLMPSRAMGQAAGRYISSTIQAQSWPLFTDSAHSGKGCACPQSVSTM
VLLLQASVLILLLASLPGSQSSPSQHLCGSSLVDALYLVCGPRGFFYTNRGRDLE
TLLALLSNLAGYEAADADPLKEKVMKMKRGIVEQCCHRPCTIYHLEDYCS 
#Tilapia 
>Oreochromis niloticus_insa 
MCFCVQLFSSMAALWLQTFSLLVLMMVSWPGSQAVGGPQHLCGSHLVDALY
LVCGDRGFFYNPRRDVDPLLGFLPPKAGGAVVQGGENEVTFKDQMEMMVKR
GIVEECCHKPCTIFDLQNYCN 
>Oreochromis niloticus_insb 
MARVSWAVSMLLLLMLCSPGGSSVPLKHLCGSHLVDALYFVCGERGFFYNPSR
THKRDVEHLLGFLSKRARQDQRLWRALSGRDEPKVKRGIVEQCCHKPCSIYHL
EGYCD 
#Japonese_Pufferfish 
>Takifugu__insa 
MAALWLQSVSLLLLMVVSSPGSQAMAPPQHLCGSHLVDALYLVCGDRGFFYN
PKRDVDSMMGILPPKAGGAAGVDNEVAEYAFKDQMEMMVKRGIVEQCCLRP
CNLLDLQNYCN 
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>Takifugu__insb 
MARLWEVSALLLLVLSSPGVSPFPAQHLCGSHLVDALYIVCGERGFFADPDRR
HKRDVEDLLGFLSNRARRQQRLWKVLSGHNEPKVKRGIVEQCCHKPCSIHHLQ
RYCD 
#Medaka 
>Oryzias latipes_insa 
MAALWLQTFSLLFLLIVSCPGSQAIAPQHLCGSHLVEALYLVCGDRGFFYTPKR
DVDPLLGLLSPKMGGATGTGAGNEVAEFAFKDQMEMLVKRGIVEQCCHKPCN
IFDLENYCN 
>Oryzias latipes_ins2 
MATLWIHTASLLILLVMSFPTTQATTLQHLCGSHLVEALYIVCGDNGFFYNPQS
AAGSPVQSLLPNTGRALSAGGETEGAPFKEQMKAIAKRNILERCCYMPCTIYDL
ASFCS 
#Platyfish 
>Xiphophorus maculatus-insa 
MAALWLQSFSLLVLLVVSWPGSQGVAPPQHLCGSHLVDALYLVCGDRGFFYS
PKRDVDHLLGFLPSKTGTGSTHGGENEVAELAFKDQMEMMVKRSGIVEQCCH
RPCSIFDLQNYCN 
#Greater_Amberjack 
>Seriola dumerili 
MAALWLQSVSLLVLLIVSWPGSQAVAPPQHLCGSHLVDALYLVCGDRGFFYNP
KRDVDPLLGFLPPKAGGAAAAGGENEVAEFAFKDQMEMMVKRGIVEQCCHKP
CNIFDLQNYCN 
#Green_Spotted_Puffer 
#Tetraodon 
>Tetraodon lineatus 
MTHMGCRVWNRRMCLWVSSVPIQHLCGSQLVDTLYFICGERGFYADGNHPHK
RDVEALLGHNEPKVKRGIVEQCCHKPCSIYHLQRYCD 
#Coelacanth 
>Latimeria menadoensis 
MALWVRVLPLFLLIALSAPSTTQAIANQHLCGSHLVEALYLVCGEKGFFYSPRG
RREIEQSLTGALCFTGVCSAGYIYILMQQGTMKEKRGIVEQCCHNTCSLYQLEN
YCN 
#Stickleback 
>Gasterosteus aculeatus 
MASLWLQSVSLLVLLVWSCPGSQAAAGPQHLCGSHLVDALYLVCGERGFFYN
PKRDVDPLMGFLPPKVGGASAAAGGENEVAEFAFKDQMEMMVKRGIVEQCC
HRPCNIFDLQNYCN 
>ciona intestinalis 
MRIAGGYLTTHPLPPDYSDDQYVYYIQYHCLSGLSLVGGDNISYCQSNGQWSG
RTPKCAVLQKCDQGFVQGDDGACTDANECNYNNGGCSHICHNFIGGFYCSCQ
RGYQLQQDQSCMD 
